

WASHINGTON, D.C.
JULY 24-26, 2025

NRG *Oncology*



2025 SUMMER MEETING
WASHINGTON DC

NRG ONCOLOGY
2025 SUMMER MEETING
Program Book

#NRG2025



Table of Contents

- 3 Welcome Message
- 4 NRG Mission Statement
- 5 Continuing Education Information
- 6 Approved CME Session Credit List
- 7 Social Media and WiFi Information
- 8 Meeting App Information
- 9 Venue Map
- 11 Meeting Agenda

SESSIONS/SPECIAL EVENTS

- 16 The NRG Podcast
- 18 Meet the Advocates: Your Partners in Progress
- 19 Summer Symposium - *“Antibody Drug Conjugates: Selection, Sequencing, & Future Strategies in Solid Tumors”*
- 21 PSC Nurse/CRA Continuing Education Session
- 23 PSC Nurse/CRA Lunch and Learn
- 24 Pathology Committee
- 26 PSC Nurse/CRA Roundtable Sessions
- 29 Investigator Development Roundtable Sessions
- 35 Translational Science Committee
- 37 Advanced Practice Providers (APP) Symposium
- 39 NCORP Town Hall
- 41 PSC Nurse/CRA Protocol Spotlights
- 43 General Session
- 45 Scientific Session
- 48 Communications & Digital Engagement Workshop
- Recording Reminder

WORKSHOP AGENDAS (CME/Non-CME)

- 50 Adaptive RT Working Group
- 51 Breast Cancer Workshop
- 52 Canadian Subcommittee
- 53 Cancer Care Delivery Research Committee
- 54 Cancer Prevention & Control Committee
- 55 Cervical/Vulvar Cancer Subcommittee
- 60 Developmental Therapeutics Committee
- 65 Developmental Therapeutics RT Subcommittee
- 66 Gastrointestinal Cancer Committee Workshop
- 67 Genitourinary Cancer Workshop
- 69 Gynecologic Cancer Committee
- 75 Head & Neck Cancer General Committee
- 77 Head & Neck Surgery Working Group
- 78 Health Care Access (HCA) Committee

- 79 HCA Older Adult SIG Breakout
- 80 HCA Research Concept Development SIG Breakout
- 81 Imaging Committee
- 82 Immunotherapy Subcommittee
- 83 Local Regional Breast Cancer Subcommittee
- 84 Lung Cancer General Committee
- 85 Medical Oncology Committee
- 86 Medical Physics Subcommittee
- 88 Ovarian Cancer Workshop
- 91 Particle Therapy Working Group
- 92 Patient-Centered Outcomes Research Committee
- 93 Radiation Oncology Committee
- 94 Radiation Oncology GYN Working Group
- 95 Radiation Oncology Theranostics Subcommittee
- 97 Rare Tumor Subcommittee
- 99 Sarcoma Working Group
- 101 Translational Science Brain Tumor Working Group
- 102 Translational Science GU Cancer Working Group
- 103 Translational Science GYN Cancer Working Group
- 105 Translational Science H&N Cancer Working Group
- 106 Translational Science Lung Cancer Working Group
- 107 Uterine Corpus Cancer Subcommittee
- 109 VA/MTF Subcommittee

INSTITUTIONAL ACCRUAL

- 111 Member Accrual

ACKNOWLEDGEMENTS

- 119 Congratulations Travel Awardees
- 120 Sponsors/Exhibitors
- 123 GSK Sponsor Advertisements
- 125 Flatiron Sponsor Advertisement
- 127 Lumonus Sponsor Advertisement
- 128 Independent Medical Education Grant Support
- 130 Future Meeting Dates and Locations



Welcome to Washington, D.C

Thank you to our members and partners who have traveled to Washington, D.C. for the Summer 2025 NRG Oncology Meeting!

We are excited to announce a new format for one of our key sessions at this year's meeting, designed to enhance the presentation of our extensive research initiatives to our members. Our Scientific Session, titled "Practice Changing Evidence Across the Spectrum of Cancer Care" will occur on Friday, July 25th from 3:00-4:30pm. This year, this session will showcase the best of NRG Oncology research in a "present-o-rama" format. The session will be divided into three segments: "Phase III Trials that Shape Clinical Practice", "Less is More: Surgical De-escalation & Patient-Centered Outcomes", and "Innovation & Insights from NRG Trials". Join us to learn how multiple NRG trials are paving the way for the future of oncology.

Our NRG 2025 Summer Symposium, titled "Antibody Drug Conjugates (ADCs): Selection, Sequencing and Future Strategies in solid Tumors", will take place on Thursday, July 24th from 8:00am-12:00pm. This session, chaired by Dr. Kathleen Moore and Dr. Paolo Tarantino, aims to provide in-depth education on the development, mechanisms of resistance, clinical applications, and adverse events of ADCs.

This year will also be the first time we host an Advanced Practice Providers (APP) Symposium on Friday, July 25th from 8:15-9:45am.

We invite everyone to join us for the NRG Reception on Friday evening from 6:00 to 8:00 PM. This is a wonderful opportunity to connect with colleagues, network with both new and familiar faces, and enjoy refreshments.

If you are new to our NRG Meeting, we encourage you to speak up and engage! We value active participation in the different meeting sessions, which are designed to foster meaningful discussion. Your contributions during the NRG Meetings will help drive the many great initiatives that NRG seeks to accomplish throughout the year.

Please browse the full meeting agenda in our Program Book to explore all the potential sessions you can participate in.


We hope you have a successful and exciting NRG Meeting experience.



Quynh-Thu Le, MD
NRG Oncology Group Chair



Robert Mannel, MD
NRG Oncology Group Chair



Norman Wolmark, MD
NRG Oncology Group Chair





Advancing Research. Improving Lives.™

NRG Oncology *Mission Statement*

NRG Oncology seeks to improve the lives of patients with cancer by conducting practice-changing multi-institutional clinical and translational research with emphases on sex-specific malignancies including gynecologic, breast, and prostate cancers and on localized or locally advanced cancers of all types.

For the Educational Objectives, we list the following:

- Inform the participants of the current state of clinical and basic oncologic research, particularly, but not exclusively as it relates to clinical trials.
- Provide participants with peer review critiques of progress (or lack of it) with the objective of self-improvement.
- Provide an opportunity to learn research administration and financial management in a cooperative group setting.
- Provide a forum for experts from diverse fields to improve research practices and patient management.

www.nrgoncology.org

#NRG2025

CONTINUING EDUCATION

CME Credit and PSC Contact Hours (Formerly CEUs)

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint Providership of The GOG Foundation, Inc. and NRG Oncology.

The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Education for physicians.

AMA PRA CATEGORY 1 CREDITS™

The GOG Foundation, Inc. designates this live activity for a maximum of **21.50 AMA PRA Category 1 Credits™**.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO CLAIM CME CREDITS

1. Scan QR Code to Complete evaluation

Overall Meeting Evaluation:
<https://s.pointerpro.com/july2025nrg>

Evaluation will not be active until the conclusion of the NRG Meeting (July 26th)



2. Select Sessions and Enter Credits being claimed

3. Click Submit and your CME certificate will automatically be emailed to you.

SYMPOSIUM

Symposium Evaluation links will be emailed to all registered attendees.



DISCLOSURE DECLARATION

In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.

OFF-LABEL STATEMENT

Some of the presentations and discussions in this session may include the off-label use of products/ devices.

CONTACT HOURS (FORMERLY CEUS)

PSC Evaluation Links will be emailed to all registered attendees.

EVALUATIONS MUST BE SUBMITTED BY: AUGUST 18, 2025

QUESTIONS

CMEs: If you have issues accessing your certificate or questions about CME please contact: cmeinfo@gog.org

PSC Contact Hours: For questions about Contact Hours (formerly CEUs) please contact: meeting-reg@NRGOncology.org

CME Credit Listing

The following sessions/workshops have been approved to receive CME credits
for the meeting July 17 - 26, 2025.

Maximum credits up to **21.50** AMA PRA Category 1 Credits™

Monday, July 21, 2025		Approved Credits	Credits Claimed
11:00 am – 1:00 pm	Medical Oncology Committee	2.00	
1:00 pm – 2:00 pm	Communications & Digital Engagement Workshop (formerly Social Media)	1.00	
3:00 pm – 4:30 pm	Developmental Therapeutics Radiation Therapy Subcommittee	1.50	

Tuesday, July 22, 2025		Approved Credits	Credits Claimed
3:00 pm – 5:00 pm	Immunotherapy Subcommittee	1.00	

Thursday, July 24, 2025		Approved Credits	Credits Claimed
11:00 am – 12:00 pm	Canadian Subcommittee	1.00	
12:00 pm – 1:30 pm	Cancer Care Delivery Research Committee (CCDR)	1.50	
12:30 pm – 2:30 pm	Developmental Therapeutics Committee	0.50	
1:45 pm – 3:15 pm	Cancer Prevention and Control Committee (CPC)	1.50	
2:30 pm – 4:30 pm	Rare Tumor Subcommittee	1.75	
3:00 pm – 5:00 pm	Translational Science Committee	2.00	
3:30 pm – 5:00 pm	Patient Centered Outcomes Research (PCOR)	1.00	

Friday, July 25, 2025		Approved Credits	Credits Claimed
8:00 am – 10:00 am	Cervix and Vulvar Cancer Subcommittee	1.75	
8:15 am – 9:45 am	NRG Advanced Practice Providers (APP) Symposium	1.00	
10:00 am – 11:30 am	NCORP Townhall	1.00	
10:00 am – 12:00 pm	Uterine Corpus Cancer Subcommittee	2.00	
1:00 pm – 3:00 pm	Ovarian Cancer Subcommittee	1.50	
3:00 pm – 4:30 pm	Scientific Session	1.50	
4:30 pm – 6:00 pm	Translational Science GYN	1.50	

Saturday, July 26, 2025		Approved Credits	Credits Claimed
7:30 am – 9:00 am	Genitourinary Cancer General Committee	1.50	
7:45 am – 9:30 am	Gynecologic Cancer Committee	1.75	

NRG2025

at your finger tips

FOLLOW



Twitter / X
@NRGOnc



Facebook
@NRG
Oncology



Instagram
@NRGOnc



LinkedIn
@NRG
Oncology



YouTube
@NRGOnc



Bluesky
@nrgonc.
bsky.social

Use the hashtag **#NRG2025** to join the conversation.



CONNECT TO WIFI

Network Login: **nrgmeeting**


Passcode: **n1r2g345**

CHECK OUT OUR MEETING WEBPAGES

The NRG2025 main agenda, session flyers, attendee information, and more are posted on our NRG2025 webpages located at:

www.nrgoncology.org/Summer2025Mtg

Continue to check these pages after NRG2025 ends as we will update this section with any available presentation slides and recordings.



Meeting App

- 1 Go to the Apple Store or Google Store
- 2 Download the CVENT Events App
- 3 Select CVENT EVENTS
- 4 Search for Event = NRG
- 5 Select: "NRG Oncology Summer 2025 Meeting"
- 6 Event ID = NRG ONCS25
(Please note there is a space after NRG)



Once you are in the NRG Oncology Summer Meeting, enter your first name, last name, and the email that you used to register for the event.

You'll receive a 6-digit verification code to your email. Enter the code on the screen. Tap the arrow.

Opt in to receive push notifications so you don't miss any important information!




Venue Map

Hotel Floor Plans


Marriott Marquis Washington, DC

Mezzanine Level




Marriott Marquis Washington, DC

Meeting Level 1



Marriott Marquis Washington, DC

Meeting Level 2




Venue Map

Hotel Floor Plans


Marriott Marquis Washington, DC

Meeting Level 3




Marriott Marquis Washington, DC

Meeting Level 4



Renaissance Washington, DC Downtown

Ballroom Level



Renaissance Washington, DC Downtown

Meeting Room Level



NRG ONCOLOGY SEMIANNUAL MEETING FINAL AGENDA

Marriott Marquis DC, Washington, D.C.
July 24 - 26, 2025 (All Sessions Eastern Time)

Thursday, July 17, 2025

1:00 pm – 2:00 pm	Local Regional Breast Cancer Working Group	Virtual Only
4:00 pm – 5:30 pm	Hematologic Malignancies Working Group	Virtual Only

Friday, July 18, 2025

12:00 pm – 2:00 pm	Translational Science Lung Cancer Working Group	Virtual Only
--------------------	---	------------------------------

Monday, July 21, 2025

11:00 am – 1:00 pm	Medical Oncology Committee	Virtual Only
12:00 pm – 1:00 pm	VA/MTF Subcommittee	Virtual Only
1:00 pm – 2:00 pm	Communications & Digital Engagement Workshop (<i>formerly Social Media</i>)	Virtual Only
1:30 pm – 3:00 pm	Imaging Committee	Virtual Only
2:00 pm – 3:00 pm	Translational Science Breast Cancer Working Group	Virtual Only
3:00 pm – 3:30 pm	Joint Imaging & Medical Physics Seminar	Virtual Only
3:00 pm – 4:00 pm	Translational Science Brain Tumor Working Group	Virtual Only
3:00 pm – 4:30 pm	Developmental Therapeutics Radiation Therapy Subcommittee	Virtual Only
3:30 pm – 5:00 pm	Medical Physics Subcommittee	Virtual Only

Tuesday, July 22, 2025

9:30 am – 10:30 am	Head & Neck Rare Tumor Working Group	Virtual Only
11:00 am – 12:30 pm	Pharmacy Subcommittee	Virtual Only
1:00 pm – 2:00 pm	QA Subcommittee (<i>Closed</i>)	Virtual Only
3:00 pm – 5:00 pm	Immunotherapy Subcommittee	Virtual Only

NRG ONCOLOGY SEMIANNUAL MEETING FINAL AGENDA

Marriott Marquis DC, Washington, D.C.
July 24 - 26, 2025 (All Sessions Eastern Time)

Thursday, July 24, 2025

6:30 am – 7:30 am	Protocol Support Committee Nurse/CRA Breakfast	Marquis 5/Level 2
6:30 am – 8:00 am	Symposium Breakfast	Marquis 6/Level 2
7:00 am – 6:00 pm	Exhibits	Marquis Foyer/Level 2
7:00 am – 6:00 pm	Registration/Information Desk	Marquis 16/Level 2
2:00 pm – 4:00 pm	General Coffee Break	Marquis Foyer/Level 2
7:30 am – 10:00 am	Patient Advocate Committee <i>(Closed)</i>	Capitol-Congress/Level 4
7:30 am – 11:50 am	Protocol Support Committee (PSC) Nurse/CRA Continuing Education Session (<i>Webinar</i> / In Person)	Marquis 5/Level 2
8:00 am – 12:00 pm	Summer Symposium - Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors (<i>Webinar</i> / In Person)	Marquis 6/Level 2
8:00 am – 10:00 am	NCORP Concept Review <i>(Closed)</i>	Union Station/Level 3
9:00 am – 10:00 am	SDMC Executive Committee Meeting <i>(Closed)</i>	Capitol Hill/Level 3
10:00 am – 11:00 am	International Members Subcommittee <i>Virtual</i>	Capitol-Congress/Level 4
10:15 am – 11:45 am	Health Care Access (HCA) Committee	Liberty M-P/Level 4
11:00 am – 12:00 pm	Canadian Members Subcommittee <i>Virtual</i>	Capitol-Congress/Level 4
11:00 am – 12:00 pm	Investigator & Career Development Committee Leadership Meeting <i>(Closed)</i>	Capitol Hill/Level 3
11:50 am – 1:15 pm	PSC Nurse/CRA – Lunch & Learn (<i>Pre-Registration Required</i>)	Independence E-H/Level 4
12:00 pm – 1:30 pm	Cancer Care Delivery Research (CCDR) Committee	Liberty M-P/Level 4
12:15 pm – 1:45 pm	Membership Committee <i>(Closed)</i>	Capitol Hill/Level 3
12:30 pm – 2:30 pm	Developmental Therapeutics Committee	Marquis 1-4/Level 2
1:00 pm – 2:45 pm	Patient Advocate Committee Poster Session	Marquis Foyer/Level 2
1:00 pm – 3:00 pm	Pathology Committee	Union Station/Level 3
1:30 pm – 4:45 pm	PSC Nurse/CRA – Continuing Education Roundtables (<i>Webinar</i> / In Person)	Independence E-H/Level 4
1:45 pm – 3:15 pm	Cancer Prevention and Control (CPC) Committee	Liberty M-P/Level 4
2:00 pm – 3:00 pm	Adaptive Radiation Therapy Working Group	Georgetown University/Level 1
2:30 pm – 4:00 pm	NRG Investigator Development Roundtable Discussion	Independence A-D/Level 4
2:30 pm – 4:30 pm	Rare Tumor Subcommittee	Marquis 1-4/Level 2
3:00 pm – 4:00 pm	Theranostics Subcommittee	Marquis 6/Level 2
3:00 pm – 4:30 pm	Ancillary Projects Committee <i>(Closed)</i>	Capitol Hill/Level 3
3:00 pm – 5:00 pm	Translational Science Committee	Liberty I-L/Level 4
3:30 pm – 5:00 pm	Patient Centered Outcomes Research (PCOR) Committee	Marquis 5/Level 2
4:00 pm – 5:00 pm	NRG Investigator Networking Session	Independence A-D/Level 4
4:30 pm – 5:30 pm	Radiation Oncology Gynecologic Working Group	Georgetown University/Level 1
5:15 pm – 6:30 pm	Committee Chairs Meeting <i>(Closed)</i>	Capitol-Congress/Level 4

NRG ONCOLOGY SEMIANNUAL MEETING FINAL AGENDA

Marriott Marquis DC, Washington, D.C.
July 24 - 26, 2025 (All Sessions Eastern Time)

Friday, July 25, 2025

6:30 am – 8:30 am	Continental Breakfast	Marquis Foyer/Level 2
7:00 am – 5:00 pm	Exhibits	Marquis Foyer/Level 2
7:00 am – 5:30 pm	Registration/Information Desk	Marquis 16/Level 2
10:00 am – 12:00 pm	General Coffee Break	Marquis Foyer/Level 2
3:00 pm – 5:00 pm	General Coffee Break	Marquis Foyer/Level 2
6:00 am – 7:30 am	Endometrial Consortium, Route 66 SPORE & Protocol 210 Meeting <i>(Closed)</i>	Union Station/Level 3
7:00 am – 8:00 am	Voting Members PI Breakfast <i>(Closed)</i>	Archives/Level 4
7:30 am – 10:00 am	Brain Tumor Core Committee <i>(Closed)</i>	Marquis 7-9/Level 2
8:00 am – 10:00 am	Cervix/Vulvar Cancer Subcommittee	Marquis 1–4/Level 2
8:00 am – 10:00 am	Head & Neck Surgical Working Group	Liberty M-P/Level 4
8:00 am – 10:00 am	Radiation Oncology Committee	Liberty I-L/Level 4
8:00 am – 12:00 pm	Breast Cancer Core Committee <i>(Closed)</i>	Marquis 6/Level 2
8:15 am – 9:45 am	Advanced Practice Provider (APP) Symposium <i>(Webinar / In Person)</i>	Marquis 5/Level 2
10:00 am – 11:30 am	NCORP Townhall	Liberty M-P/Level 4
10:00 am – 12:00 pm	Head & Neck Cancer Core Committee <i>(Closed)</i>	Capitol-Congress/Level 4
10:00 am – 12:00 pm	Sarcoma Subcommittee	Howard University/Level 1
10:00 am – 12:00 pm	Uterine Corpus Cancer Subcommittee	Marquis 1–4/Level 2
10:15 am – 11:45 am	Neurosurgical Working Group	Le Droit Park-Shaw/Level 3
10:15 am – 11:45 am	Particle Therapy Working Group	Liberty I-L/Level 4
10:30 am – 11:45 am	PSC Nurse/CRA – Continuing Education Session – Protocol Spotlights <i>(Webinar / In Person)</i>	Marquis 5/Level 2
12:00 pm – 1:00 pm	General Session	Marquis 5/Level 2
1:00 pm – 2:00 pm	Head & Neck Patient-Reported Outcomes/Cost Effectiveness Working Group	Monument/Level 4
1:00 pm – 2:00 pm	Head & Neck Skin Working Group	<i>Virtual Only</i>
1:00 pm – 2:00 pm	HCA Committee Breakout Session: Research Concept Development SIG	Howard University/Level 1
1:00 pm – 2:00 pm	Translational Science Head & Neck Cancer Working Group	Liberty I-L/Level 4
1:00 pm – 3:00 pm	Genitourinary Cancer Core Committee <i>(Closed)</i>	Le Droit Park-Shaw/Level 3
1:00 pm – 3:00 pm	Lung Cancer Core Committee <i>(Closed)</i>	Union Station/Level 3
1:00 pm – 3:00 pm	Ovarian Cancer Subcommittee	Marquis 1 - 4/Level 2
1:15 pm – 2:45 pm	Brain Tumor General Committee	Marquis 7- 9/Level 2
1:15 pm – 2:45 pm	PSC Education & Training Subcommittee <i>(Closed)</i>	Capitol Hill/Level 3
1:15 pm – 2:45 pm	PSC Mentorship Subcommittee <i>(Closed)</i>	Chinatown/Level 3
1:15 pm – 2:45 pm	PSC Protocol Review Subcommittee <i>(Closed)</i>	Mount Vernon Square/ Level 3
1:15 pm – 2:45 pm	PSC Quality Control & Communications Subcommittee <i>(Closed)</i>	Marquis 13/Level 2
2:00 pm – 3:00 pm	Head & Neck Previously Untreated Locoregionally Advanced Working Group	<i>Virtual Only</i>
2:00 pm – 3:00 pm	HCA Committee SIG Leadership Meeting <i>(Closed)</i>	Monument/Level 4
3:00 pm – 4:30 pm	Scientific Session	Marquis 5/Level 2
4:30 pm – 5:30 pm	HCA Committee Breakout Session: Older Adult Research SIG	Howard University/Level 1
4:30 pm – 6:00 pm	Head & Neck Cancer General Committee	Liberty I - L/Level 4
4:30 pm – 6:00 pm	PSC CTN/CRA Subcommittee Joint Meeting <i>(Closed)</i>	Capitol-Congress/Level 4
4:30 pm – 6:00 pm	Translational Science Genitourinary Cancer Working Group	Le Droit Park-Shaw/Level 3
4:30 pm – 6:00 pm	Translational Science GYN Cancer Working Group	<i>Virtual Only</i>
4:30 pm – 6:15 pm	Lung Cancer General Committee	Liberty M - P/Level 4
5:00 pm – 7:00 pm	Korean Gynecologic Oncology Group	Union Station/Level 3
6:00 pm – 8:00 pm	NRG Oncology Reception	Mezzanine Foyer/Level 2

NRG ONCOLOGY SEMIANNUAL MEETING FINAL AGENDA

Marriott Marquis DC, Washington, D.C.
July 24 - 26, 2025 (All Sessions Eastern Time)

Saturday, July 26, 2025

6:30 am – 10:00 am	Continental Breakfast	Marquis Foyer/Level 2
7:00 am – 11:00 am	Exhibits	Marquis Foyer/Level 2
7:00 am – 11:00 am	Registration/Information Desk	Marquis 16/Level 2
6:30 am – 8:00 am	Surgical Oncology Committee	Archives/Level 4
7:30 am – 9:00 am	Gastrointestinal Colorectal Cancer Core Committee <i>(Closed)</i>	Capitol-Congress/Level 4
7:30 am – 9:00 am	Genitourinary Cancer General Committee	Marquis 7- 9/Level 2
7:30 am – 9:00 am	Protocol Operations Management (POM) Committee <i>(Closed)</i>	Chinatown/Level 3
7:45 am – 9:30 am	Gynecologic Cancer Committee	Marquis 1 - 4/Level 2
8:00 am – 10:30 am	PSC Core Executive Committee <i>(Closed)</i>	Capitol Hill/Level 3
9:00 am – 12:00 pm	Breast Cancer General Committee	Marquis 5/Level 2
9:15 am – 10:45 am	Gastrointestinal Non-Colorectal Cancer Core Committee <i>(Closed)</i>	Capitol-Congress/Level 4
11:00 am – 12:30 pm	Gastrointestinal Cancer General Committee	Marquis 6/Level 2



NRG *Oncology*

2025 SUMMER MEETING
WASHINGTON DC

NRG ONCOLOGY

*Special Events, Sessions, and
Workshops*

#NRG2025

THE NRG ONCOLOGY PODCAST

Moving the needle in cancer care



with Co-hosts

Stephen Chun, MD

&

Lauren Henke, MD



**2025 ACRO
Media Award Recipient**

LISTEN ON:



SPOTIFY



APPLE
PODCASTS



YOUTUBE



AMAZON
MUSIC



TOPICS:

LUNG CANCER IN NRG ONCOLOGY

Interview with Dr. Jeff Bradley, outgoing Lung Committee Chair

Available after the #NRG2025 General Session


NRG ONCOLOGY MEMBERSHIP

Interview with Dr. David Miller, Committee Chair

Available after the #NRG2025 Scientific Session



SPECIAL
EPISODE



MEET THE ADVOCATES:

Your Partners in Progress

Presented by the NRG Oncology Patient Advocates



WHEN: THURSDAY, JULY 24 | 1:00-2:45PM



WHERE: MARQUIS FOYER, LEVEL 2

Join the NRG Oncology Patient Advocate Committee for an engaging poster session highlighting the vital role of patient advocacy in clinical trials and cancer research. Our advocates will be on hand to share stories, answer questions, and spark conversation on how collaborative engagement improves outcomes across the research lifecycle.

Featured Topics:

- Bridging the gap between clinicians & patients
- Advocacy-driven improvements in trial recruitment
- Fundraising in action: NRG's Health Care Access Fellowship
- The advocate's voice in research strategy
- Tackling barriers to community participation in trials
- Educating patients, researchers, policymakers & peer

Stop by, say hello, and explore the power of partnership in clinical research.

Symposium - Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

Thursday, July 24, 2025 - 8 - 12 pm Eastern

Program Chair - Kathleen Moore, MD
Co-Chair - Paolo Tarantino, MD

Program Description

The use of antibody-drug conjugate (ADC) therapy has ushered in a new era in oncology, significantly transforming the management of a range of solid tumor malignancies. This session offers a valuable opportunity to explore the expanding role of ADCs in the treatment of ovarian, cervical, endometrial, breast, lung, genitourinary and gastrointestinal cancers, highlighting their impact on clinical practice and patient outcomes. The latest practice-changing clinical trial results will be provided and reviewed in context with challenging clinical practice scenarios in cancer patients treated with ADC. Expert led discussions will provide evidence-based perspectives regarding important clinically relevant topics in drug selection, biomarkers, sequencing, and toxicity management. We will also review the future landscape of care and current as well as upcoming clinical trials. This timely and clinically relevant session aims to equip attendees with actionable knowledge that can be immediately applied in oncology practice.

Interactive case vignettes will offer practical guidance on patient selection, therapeutic strategies, and the management of adverse effects associated with ADCs. Additionally, ongoing and planned pivotal clinical trials will be discussed and the future of clinical trial design in the era of current ADC and novel future therapies will be explored.

Learning Objectives

Following this activity, participants will be better able to:

- **Explain** the development and mechanism of action of antibody-drug conjugates (ADCs) and identify mechanisms of resistance.
- **Discuss** the clinical application of ADCs in the treatment of gynecologic, breast, lung, genitourinary (GU), and gastrointestinal (GI) malignancies.
- **Recognize** and **Manage** adverse events associated with ADC therapy.

Target Audience

This symposium is intended for a broad oncology-focused audience, including members and non-members. Participants may include physicians, research staff, early-career investigators, clinical research associates, basic scientists, medical physicists, clinical trial nurses, patient advocates, and other healthcare professionals involved in cancer treatment and research.

[See presentation agenda on next page](#)

Summer 2025 Symposium

Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

Thursday, July 24, 2025 – NRG Oncology Semiannual Meeting - Washington, DC

Presentation Agenda

Program Chair: Kathleen Moore, MD / Co-Chair Paolo Tarantino, MD

Presentation Agenda		
Time	Topic/Title	Speaker/Moderator
6:30 am	Full Breakfast Buffet	
8:00 am	Welcome/Opening Remarks	Kathleen Moore, MD
8:05-9:35am	Session 1 <i>"Selection and ADCs in Gynecologic, Breast, Lung, GU and GI Cancers"</i>	Moderators: Ian Krop, MD
8:05 – 8:20	How do ADCs actually work? Magic Bullets or Just Fancy Chemotherapy?	Patricia LoRusso, DO, PhD
8:20 – 8:35	ADCs in Breast Cancer	Ian Krop, MD
8:35 – 8:50	Expanding ADCs in Lung Cancer	Biagio Ricciuti, MD
8:50 – 9:05	Evolution of ADCs in GI Oncology	Michael Cecchini, MD
9:05 – 9:20	Evolution of ADCs in GU Oncology	Shilpa Gupta, MD
9:20 - 9:35 am	Panel Discussion with Q/A	ALL
9:35 – 10:50 am	Session 2: <i>"Selection, Sequencing and Mechanism of Resistance- Patient Centric Development of ADCs"</i>	Moderator: Paolo Tarantino, MD
9:35 – 9:55	ADC Landscape in Gynecologic Cancers	Ramez Eskander, MD
9:55 - 10:15	Mechanisms of Resistance and Impact on ADC Sequencing	Paolo Tarantino, MD
10:15 – 10:35	How "Manageable" are ADC side effects? The Patient Perspective	Julia Maues
10:35 – 10:50	Panel Discussion with Q/A	ALL
10:50 – 11:00	Coffee Break	
11:00 – 12:05 pm	Session 3: <i>"Future Developments, Optimization, and Safety"</i>	Moderator: Joyce Liu, MD –
11:00 – 11:20	New Frontiers of ADCs: ISACs, DACs, bispecific ADCs and beyond	Abdul Rafel Raqash, MD
11:20 – 11:40	Boosting the Activity of ADCs with Combinations	Leif W. Ellisen, MD, PHD
11:40 - 12:00	Regimen Optimization and Regulatory Considerations in ADC Development	Lauren Price, PharmD
12:00 – 12:10 pm	Panel Discussion with Q/A	ALL
12:10 pm	Closing Remarks	Kathleen Moore, MD and Paolo Tarantino, MD

Protocol Support Committee

Nurse / Clinical Research Associate

Continuing Education Session



Thursday, July 24, 2025

7:30 am - 11:50 am ET

Morning Session (7:30 am - 11:50 am ET) In-Person & Virtual

Lunch & Learn (11:50 am - 1:15 pm ET) In-Person Only

PROGRAM FACILITATORS

Cynthia Licavoli, RN, BSN, MHA

Marissa Weiss, MBA

Jacqueline Ludwig, RN, BSN, CCRP

SPEAKERS

Sharon Hartson Stine, MS, BA

NRG Oncology Welcome & Updates

Kandie Dempsey, DBA, MS, RN, OCN

PRO Inception to Impact

Ying Liu, MD, MPH

Introduction to Pragmatic Clinical Trials

Kimberly Williams, MHCM

Patient Perspective on Pragmatic Clinical Trials

Elaina Harper, BS

Logistics of Data Management for Pragmatic Trials

Sara McCarthy, MS, RN

Logistics of AE Reporting for Pragmatic & AE/SAE Reporting Updates

Cynthia Licavoli, RN, BSN, MHA

NRG Oncology Protocol Support Committee

Nancy Fusco, RN, BSN, CCRP

NRG Oncology Mentorship Program

Caroline Porter, MS, MBA, PMP

CTSU Updates

Mary Jo Antonelli, MBA, MHA

NRG Oncology Quality Assurance Update

Thomas George, MD

*From Breakthroughs to Bold Futures:
The Next Frontiers in Cancer Treatment*

Cynthia Licavoli, RN, BSN, MA

Jacqueline Ludwig, RN, BSN, CCRP

Wrap up & Evaluations

Jennifer Dill, BS, CCRP

*Lunch & Learn Session: Discuss, Share & Strategize
Offered In-Person only*

This activity has been approved by the Virginia Nurses Association to award contact hours.

*The Virginia Nurses Association is accredited as an approver of nursing continuing professional development
by the American Nurses Credentialing Center's Commission on Accreditation.*

Session Title	PSC Nurse/CRA- Continuing Education Session		
Date	07/24/2025	Chair(s)	Cynthia Licavoli, RN, BSN, MHA
Time	7:30 am-11:50 am ET	Vice Chair(s)	Marissa Weiss, MBA & Jacqueline Ludwig, RN, BSN, CCRP

Meeting Agenda

Time	Topic	Presenter
7:30 am-7:40 am	Introduction/Welcome	Cynthia Licavoli, RN, BSN, MHA & Jacqueline Ludwig, RN, BSN, CCRP
7:40 am- 7:50 am	NRG Oncology Welcome & Updates	Sharon Hartson Stine, MS, BA
7:50 am – 8:15 am	Patient Reported Outcomes (PRO) Inception to Impact	Kandie Dempsey, DBA, MS, RN, OCN
8:15 am- 8:35 am	Introduction to Pragmatic Clinical Trials	Kathleen Moore, MD
8:35 am- 8:45 am	Patient Perspective on Pragmatic Clinical Trials	Kimberly Williams, MHCM
8:45 am – 8:55 am	Logistics of Data Management for Pragmatic Trials	Elaina Harper, BS
8:55 am -9:25 am	Logistics of AE Reporting for Pragmatic & AE/SAE Reporting Updates	Sara McCartney, MS, RN
9:25 am – 9:35 am	Break	
9:35 am-9:45 am	NRG Oncology Protocol Support Committee	Cynthia Licavoli, RN, BSN, MHA
9:45 am- 9:55 am	NRG Oncology Mentorship Program	Nancy Fusco, RN, BSN, CCRP
9:55 am- 10:05 am	CTEP Website Updates	Grace Mishkin, PhD, MPH
10:05 am-10:30am	CTSU Updates	Caroline Porter, MS, MBA, PMP
10:30 am-10:55am	NRG Oncology Quality Assurance Update	Mary Jo Antonelli, MBA, MHA
10:55 am-11:45am	From Breakthroughs to Bold Futures: The Next Frontiers in Cancer Treatment	Thomas George, MD
11:45am-11:50am	Wrap up & Evaluations	Cynthia Licavoli, RN, BSN, MHA & Jacqueline Ludwig, RN, BSN, CCRP

Additional Notes: *This activity has been approved by the Virginia Nurses Association to award contact hours. The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.*

Session Title	PSC Nurse/CRA- Protocol Support Committee Lunch & Learn		
Date	07/24/2025	Chair(s)	Cynthia Licavoli, RN, BSN, MHA
Time	11:50 am-1:15 pm ET	Vice Chair(s)	Marissa Weiss, MBA & Jacqueline Ludwig, RN, BSN, CCRP

Meeting Agenda

Time	Topic	Presenter
	Lunch & Learn: Discuss, Share & Strategize	Jennifer Dill, BS, CCRP

Additional Notes: In-person only offering

This activity has been approved by the Virginia Nurses Association to award contact hours. The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Pathology Committee



Thursday, July 24, 2025
1:00-3:00 pm ET

2025 SUMMER MEETING
WASHINGTON DC

#NRG2025

Session Co-Chairs



Jeffrey Simko, MD, PhD
Pathology Chair



Tan Ince, MD, PhD
*Pathology Vice
Chair*



Tanner Freeman, MD, PhD
Pathology Vice Chair

Presenters



Alyssa Bujnak, MD
*University of California,
Irvine*

NRG Oncology/GOG-0240 NIH Cancer Moonshot: Molecular Characterization of Advanced and Recurrent Cervical Carcinoma



Suzanne Baldwin
NRG Oncology

Specimen and Data Access Procedures for Research



Tanner Freeman, MD, PhD
Pathology Chair

NRG Oncology Pittsburgh Biobank update, trial and pathology projects update, and other business.

Session Title	Pathology Committee		
Date	July 24 th , 2025	Chair(s)	Jeffry Simko, MD, PhD
Time	1:00 – 3:00 pm ET	Vice Chair(s)	Tan Ince, MD, PhD Tanner Freeman, MD, PhD

Learning Objectives

Following this activity, participants will be better able to:

1. Understand and explain the molecular characterization of advanced and recurrent cervical carcinoma
2. Understand the current capabilities of the NRG Oncology Biobank Pittsburgh
3. Understand how to contact the NRG Oncology Biobank Pittsburgh
4. Discuss the future goals of the NRG Oncology Biobank Pittsburgh
5. Understand and explain how to access NRG biospecimens and data

Meeting Agenda

Time	Topic	Presenter
1:00 – 1:05 pm ET	Welcome and Introductions	Tanner Freeman, MD, PhD (University of Pittsburgh)
1:05 – 1:50 pm ET	NRG Oncology/GOG-0240 NIH Cancer Moonshot: Molecular Characterization of Advanced and Recurrent Cervical Carcinoma	Alyssa C. Bujnak, MD (University of California, Irvine)
1:50 – 2:35 pm ET	NRG Oncology Biobank Pittsburgh - 2025 Update	Tanner Freeman, MD, PhD
2:35 – 2:45 pm ET	Trial and Pathology Project Updates	Tanner Freeman, MD, PhD
2:45 – 2:55 pm ET	Specimen and Data Access Procedures for Research	Suzanne Baldwin (NRG Oncology) / Tanner Freeman, MD, PhD
2:55 – 3:00 pm ET	Other Business and Closing Remarks	Tanner Freeman, MD, PhD

:

Protocol Support Committee

Roundtable Sessions

Thursday, July 25, 2024

1:30 pm - 4:45 pm ET

Nurse / Clinical Research Associate
Continuing Education Sessions

PROGRAM FACILITATORS

Cynthia Licavoli, RN, BSN, MHA

Marissa Weiss, MBA

Jacqueline Ludwig, RN, BSN, CCRP

TOPICS

- Brain Cancer Protocols
- Breast Cancer Protocols (BR007/BR008/BR009)
- Colorectal Cancer Protocol (Glo08)
- NRG-CC015
- GI FORTE (NRG-CC005)*
- Genitourinary Cancer Protocols
- GYN Cancer Protocols
- Head & Neck Cancer Protocols
- Lung Cancer Protocols
- NRG Oncology Biospecimen Banks
- Patient Reported Outcomes (PRO) Compliance*
- NRG Oncology Quality Assurance Program*
- NRG Oncology Regulatory Requirements
- NRG Oncology Communications
- Adverse Event Reporting*
- IROC Radiation Therapy/Diagnostic Imaging/TRIAD
- CTSU
- RECIST Practice
- Best Practice: Organizing Your Workday: Part 1*
- Best Practice: Organizing Your Workday: Part 2*
- Best Practice: Study Start Up, Implementation & Management*
- Best Practice: Site Administrator
- Best Practice: Onboarding New Coordinators*
- PSC Mentorship

**In-person with limited topics offered to virtual audience*

*This activity has been approved by the Virginia Nurses Association to award contact hours.
The Virginia Nurses Association is accredited as an approver of nursing continuing professional development
by the American Nurses Credentialing Center's Commission on Accreditation.*

Session Title	PSC Nurse/CRA- Continuing Education Session: Roundtables		
Date	07/24/2025	Chair(s)	Cynthia Licavoli, RN, BSN, MHA
Time	1:30 pm- 4:45 pm ET	Vice Chair(s)	Marissa Weiss, MBA & Jacqueline Ludwig, RN, BSN, CCRP

Meeting Agenda

Time	Topic	Presenter
	Brain NRG Protocols	Liz Wise, AAS, CCRC
	Breast (NRG BR007/BR008/BR009) Protocols	Martha Duncan, RN, MSN, Kristen Kotsko, RN, BSN & Eliana Harper, BS
	Colorectal (NRG GI008) Protocols	Mary Pat Matisko, RN, BSN & Andrew Pearlman, BA
	NRG CC015	Julienne Bower PhD & Patricia Ganz, MD
	GI FORTE (NRG CC005)*	Cheryl Leow, MA, Kristen Kotsko, RN, BSN & Izabela Frak
	Genitourinary (GU) NRG Protocols	Liz Wise, AAS, CCRC
	GYN NRG Protocols	Lisa Barry, MEd, CCRP
	Head & Neck NRG Protocols	Aaron Johnson, MA
	Lung NRG Protocols	Aaron Johnson, MA
	NRG Oncology Biospecimen Bank	Lisa Beaverson BA, CCRP, Melanie Finnigan & Leslie Longoria
	Patient Reported Outcomes (PRO) Compliance*	Marcie Ritter, PhD & Kandie Dempsey, DBA, MS, RN, OCN
	NRG Oncology Quality Assurance Program*	Rebecca Beaulieu, MS, CCRC & Alison Ivey, RN MS MBA OCN CCRP
	NRG Oncology Regulatory Requirements	Judy Langer, BS & Tammy Rider, MBA
	NRG Oncology Communications	Michelle Shepard, Angie Pier & Cathy Galoppo

Summer 2025 – Washington D.C. Semiannual Meeting Agenda

Adverse Event Reporting*	Sara McCartney, MS, RN & Cortney Montgomery, RN, CCRP, CBCN
IROC Radiation Therapy/Diagnostic Imaging/TRIAD	Jessica Lowenstein, MS, DABR & Denise Manfredi, BS, RT (T)(ARRT)
CTEP	Grace Mishkin, PhD, MPH
CTSU	Caroline Porter, MS, MBA, PMP & Rachel Albershardt, MS, CCRP
RECIST Practice	Elena Nelson, MBA, CCRC
Best Practice: Organizing Your Workday: Part 1*	Cynthia Licavoli, RN, BSN, MHA & Erin McCaig, RN, BSN
Best Practice: Organizing Your Workday: Part 2*	Tiffany Elsea, BA, CCRP, Belinda Buehl, BS & Erin Fukaya, MS
Best Practice: Study Start Up, Implementation & Management*	Haley Kelly, RN, BSN & Mahjabin Noroozi, PharmD
Best Practice: Site Administrator	Alex Kudryashev MS, CCRP
Best practice: Onboarding New Coordinators*	Pam Mason RN, BSN, CCRP & Tiffany Elsea, BA, CCRP
PSC Mentorship	Nancy Fusco, RN, BSN, CCRP & Sarah Lewis, RN, BSN, OCN

Additional Notes:

Roundtable Discussions: 20-minute rounds every 25 minutes providing 8 sessions for participants:

- **Limited topics offered to virtual audience***
- **In-person attendees refer to onsite handout provided, not all topics will be offered each session.**

This activity has been approved by the Virginia Nurses Association to award contact hours. The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Investigator Development Roundtable Sessions

#NRG2025



Thursday, July 24, 2025

2:30 - 4:00pm ET

Independence A-D, Level 4

Roundtables Format

In a novel interactive format, attendees will be able to circulate to various roundtables, where they can interact with NRG Oncology leaders, learn more about the roundtable topic, and ask questions of the NRG Oncology leaders. We will run four periods, with time in between periods for attendees to walk to another roundtable whose topic may be of interest.

Session Co-Chairs



Vinai Gondi, MD
Chair



Priya Rastogi, MD
Vice Chair



Angeles Secord, MD
Vice Chair

2:30-2:35pm

Welcome & Introductions

2:35-3pm

Session 1

3:05-3:30pm

Session 2

3:30-3:55pm

Session 3

3:55-4pm

Closing Remarks

Join us for the Networking Session that will
immediately follow from 4:00-5:00pm ET

Roundtable Topics and Discussion Facilitators

TABLE 1 - NCORP

- Familiarize yourself with the Division of Cancer Prevention(DCP)/NCI Community Oncology Research Program (NCORP) and their research priorities.
- Understand how to advance a clinical trial and/or apply for research funding through the DCP/NCORP mechanism.



Deborah Bruner, RN, PhD



Brandy Heckman-Stoddard, PhD, MPH



Erica Field, MPH, MHA



Kate Castro, MS, RN

TABLES 2 - 5 DISEASE SITE COMMITTEE ACTIVITY

- Learn how to become a General Member and a Core Committee Member of the NRG Disease-Specific Scientific Committees.
- Understand the roles, responsibilities and opportunities associated with these Scientific Committees.
- Learn from a highly experienced Disease Site Chairperson and clinical trialist about how you can develop a research idea into a successful NRG clinical trial.
- Delve into the nuts and bolts about the multiple ways you can build your research interests through NRG Oncology

Table 2 - BREAST



Julia White, MD

Table 3 - LUNG



Kristin Higgins, MD

Table 4 - GENITOURINARY



Paul Nguyen, MD

Table 5 - GYNECOLOGIC



Paul DiSilvestro, MD



Floor Backes, MD



Roisin O'Cearbhail, MD

TABLE 6 - STATISTICS



Kathryn Winter, MS

- Understand how the NRG Biostatistics team supports the development, conduct and reporting of a clinical trial.
- Learn how best to collaborate with NRG Biostatisticians to support your research/trial.

TABLE 7 - PROTOCOL DEVELOPMENT



Nancy Soto

- Understand the various steps to developing a clinical trial protocol within NRG Oncology.
- Learn about the roles/responsibilities of NRG Oncology staff and headquarters in helping you develop a clinical trial concept and protocol.

TABLE 8 - NCI/CTEP PROCESSES (BRAIN)



Bhupinder Mann, MD

- Learn about the NCI's Cancer Evaluation Program (CTEP) from NCI Program Officers.
- Understand the key phases of the protocol lifecycle, CTEP involvement, and tips for success.

TABLE 9 - NCI/CTEP PROCESSES (BREAST)



Larissa Korde, MD

- Learn about the NCI's Cancer Evaluation Program (CTEP) from NCI Program Officers.
- Understand the key phases of the protocol lifecycle, CTEP involvement, and tips for success.

TABLE 10 - TRANSLATIONAL/LABORATORY RESEARCH



Andy Nixon, MD



Dmitriy Zamarin, MD

- Explore the multiple ways that Translational research is incorporated into NRG Oncology clinical trials.
- Learn about the NRG Biospecimen Bank and understand how you can explore your research interests through biospecimens from NRG Oncology clinical trials.

TABLE 11 - ACADEMIC CAREER GROWTH THROUGH ENGAGEMENT WITH NRG



Karen Hoffman, MD



Atif Khan, MD

- Real-life examples of career progression for NRG investigators.
- Learn about opportunities for investigator involvement, networking, and mentorship within NRG.

Session Title	Early Career & Investigator Development Committee – Investigator Development Roundtable Session		
Date	July 24, 2025	Session Chair(s)	Vinai Gondì, MD, Priya Rastogi, MD, Angeles Alvarez Secord, MD, Katherine Moxley, MD
Time	2:30 – 4:00 pm ET	Location	Independence A-D

Meeting Agenda

Time	Topic	Presenter
2:30 - 2:35pm	Welcome & Introductions	Vinai Gondì, MD
2:35 – 3:00pm	Session 1 - Attendees will pick their 1 st table	
3:05 – 3:30pm	Session 2 - Attendees will pick their 2 nd table	
3:30 – 3:55pm	Session 3 - Attendees will pick their 3 rd table	
3:55 – 4:00pm	Closing Remarks	Vinai Gondì, MD

Table Topics

Table 1 – Overview of NCI Community Oncology Research Program (NCORP)	Brandy Heckman-Stoddard, PhD, MPH, Kate Castro, MS, RN, Deborah W. Bruner, RN, PhD, & Erica Field, MPH, MHA
Table 2 – NRG Disease Site Committee Activity (Breast)	Julia White, MD
Table 3 – NRG Disease Site Committee Activity (Lung)	Kristin Higgins, MD
Table 4 – NRG Disease Site Committee Activity (GU)	Paul Nguyen, MD
Table 5 – NRG Disease Site Committee Activity (GYN)	Floor Backes, MD, Paul DiSilvestro, MD, & Roisin O’Cearbhaill, MD
Table 6 – NRG Trials: Statistics	Kathryn Winter, MS
Table 7 – NRG Trials: Protocol Development	Nancy Soto
Table 8 – NCI/CTEP Processes (Brain)	Bhupinder Mann, MD
Table 9 – NCI/CTEP Processes (Breast)	Larissa Korde, MD
Table 10 – Translational/Laboratory Research	Andy Nixon, MD & Dmitriy Zamarin, MD
Table 11 – Academic Career Growth Through Engagement With NRG	Karen Hoffman, MD & Atif Khan, MD

Additional Notes:

This in-person-only session will feature three rounds of roundtable discussions, each lasting 25 minutes. Attendees are encouraged to review the list of presenters and table topics in advance and select the discussions they would like to join. Please refer to the accompanying flyer or handout for a comprehensive overview of the available topics and facilitators.

Attendees are invited to stay for the Investigator Networking Session immediately following, from 4:00–5:00 PM, for an opportunity to continue conversations and build new connections.

Translational Science *Committee*



Thursday, July 24, 2025
3:00-5:00 pm ET

2025 SUMMER MEETING
WASHINGTON DC

#NRG2025

Session Co-Chairs



Michael Birrer, MD, PhD
TSC Chair



Vered Stearns, MD
TSC Vice Chair



Adam Dicker, MD, PhD
TSC Vice Chair

Presenters



Alyssa Bujnak, MD
*University of California,
Irvine*

NRG Oncology/GOG-0240 NIH Cancer Moonshot:
Molecular Characterization of Advanced and
Recurrent Cervical Carcinoma



Xiang Zhang, PhD
*Baylor College of
Medicine*

Proposed Pilot Project: Integrating Baseline ctDNA
Detection and Immune Signature Analysis to
Predict Pathologic Complete Response in
HER2-Positive Breast Cancer:
Insights from the NSABP B-52 Trial



Phuoc Tran, MD, PhD
University of Maryland

Proposed Pilot Project: Validation of a Multimodal
Artificial Intelligence Biomarker in the NRG-GU006
Prostate Cancer Trial



Michael Birrer, MD, PhD

Translational Science Committee Updates

Session Title	Translational Science Committee		
Date	July 24 th , 2025	Chair(s)	Michael Birrer, MD, PhD
Time	3:00 – 5:00 pm ET	Vice Chair(s)	Adam Dicker, MD, PhD; Vered Stearns, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Understand and explain the role of ctDNA and immune signatures in breast cancer management
2. Understand and explain the role of Artificial Intelligence in prostate cancer
3. Understand and explain the molecular characterization of advanced and recurrent cervical carcinoma

Meeting Agenda

Time	Topic	Presenter
3:00 – 3:05 pm ET	Welcome and Introductions	Michael Birrer, MD, PhD (University of Arkansas)
3:05 – 3:35 pm ET	Proposed Pilot Project: Integrating Baseline ctDNA Detection and Immune Signature Analysis to Predict Pathologic Complete Response in HER2-Positive Breast Cancer: Insights from the NSABP B-52 Trial	Xiang, Zhang, PhD (Baylor College of Medicine)
3:35 – 4:05 pm ET	Proposed Pilot Project: Validation of a Multimodal Artificial Intelligence Biomarker in the NRG GU006 Prostate Cancer Trial	Phuoc Tran, MD, PhD (University of Maryland)
4:05 – 4:40 pm ET	NRG Oncology/GOG-0240 NIH Cancer Moonshot: Molecular Characterization of Advanced and Recurrent Cervical Carcinoma	Alyssa C. Bujnak, MD (University of California, Irvine)
4:40 – 4:55 pm ET	Translational Science Committee Updates	Michael Birrer, MD, PhD
4:55 – 5:00 pm ET	Concluding Remarks	Michael Birrer, MD, PhD

Advanced Practice Providers (APP) Symposium

Friday, July 25, 2025
8:15-9:45 am ET

NRG
Oncology
2025 SUMMER MEETING
WASHINGTON DC
#NRG2025

Session Chairs



Deborah Bruner,
PhD, RN, FAAN



Kathleen Castro, RN, MS



**Christa Braun-Inglis, DNP, APRN-
Rx, FNP-BC, AOCNP**



Melyssa Foust, MSN, RN, OCN

Presenters

Review of APP CTEP Policy and NCORP Guidelines
Kathleen Castro, RN, MS

Integrating APPs in other Research Bases
and NRG

Christa Braun-Inglis, DNP, APRN-Rx, FNP-BC, AOCNP

Panel Discussion

Moderator:
Kathleen Castro

Panelists:



Rajiv Panikkar, MD
Geisinger NCORP



Harmony Bowles, PharmD, BCOP
New Mexico NCORP

Stephen Chun, MD & Molly Tate, APP
MD Anderson Cancer Center

Tashanna Myers, MD & Sarah Irish, APP
Baystate Medical Center

Angie Wellman, APP
Columbus NCORP



Session Title	NRG Advanced Practice Providers (APP) Symposium		
Date	July 25, 2025	Session Chairs	Deb Bruner, Kathleen Castro, Christa Braun-Inglis, Melyssa Foust
Time	8:15 – 9:45amET		

Learning Objectives

Following this activity, participants will be better able to:

1. Identify the different roles APPs can serve in NCI sponsored research.
2. Elevate APP involvement in clinical research at practice sites.
3. Understand how APPs can add value to protocol review and development.

Meeting Agenda

Time	Topic	Presenter
8:15 – 8:20am	Introduction and Welcome	Deb Bruner, PhD, NRG NCORP PI
8:20 – 8:25am	Review of APP CTEP Policy and NCORP Guidelines	Kathleen Castro, RN, MS
8:25 – 8:35am	Integrating APPs in NRG and other Research Bases	Christa Braun-Inglis, DNP, APRN-Rx, FNP-BC, AOCNP; Melyssa Foust, MSN, RN, OCN
8:35 – 9:35am	Panel Discussion	Moderator: Kathleen Castro, RN, MS Panelists: Rajiv Panikkar, MD (Geisinger NCORP) Angie Wellman, APP (Columbus NCORP) Harmony Bowles, PharmD (New Mexico NCORP) Stephen Chun, MD; Molly Tate, APP (MD Anderson Cancer Center) Tashanna Myers, MD; Sarah Irish, APP (Baystate Medical Center)
9:35 – 9:45am	Next steps	Christa Braun-Inglis, DNP, APRN-Rx, FNP-BC, AOCNP

NCORP Town Hall

Friday, July 25, 2025
10-11:30 am ET



2025 SUMMER MEETING
WASHINGTON DC

#NRG2025

Presenters

Session Chairs



Deborah Bruner,
PhD, RN, FAAN



Lisa Kachnic, MD

NRG-CC005/FORTE Update

Robert Schoen, MD
University of Pittsburgh
NRG-CC005 PI



NRG-CC015: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer – HEAL-ABC

Patricia Ganz, MD
UCLA Health
Jonsson Comprehensive Cancer Center
NRG-CC015 Co-PI



Reporting of a positive multi-center phase III trial of SRS vs. HA-WBRT

Ayal Aizer, MD, MHS
Dana-Farber Cancer Institute



NCI NCORP Update

Kathleen Castro, RN, MS
Operations Lead for
CCDR/Program Officer,
NCI Health Care Delivery Research Program



NCI CCDR Update

Rachelle Brink, PhD
Program Director/NCORP CCDR Project Scientist,
NCI Health Care Delivery Research Program



Session Title	NCORP Town Hal		
Date	July 25, 2025	Chair(s)	Deb Bruner, PhD, RN, FAAN; Lisa Kachnic, MD
Time	10:00 – 11:30am	Vice Chair(s)	

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss proposed and ongoing NRG NCORP research trials.
2. Apply procedures and best practices to implement a protocol within NCORP.
3. Learn about opportunities in CCDR and CPC clinical trials.

Meeting Agenda

Time	Topic	Presenter
10:00 – 10:10am	Welcome, NRG NCORP updates	Lisa Kachnic, MD, NCORP PI
10:10 – 10:20am	NRG-CC005/FORTE update	Robert Schoen, MD, NRG-CC005 PI
10:20 – 10:35am	NRG-CC015: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer—HEAL-ABC	Patricia Ganz, MD, NRG-CC015 Co-PI
10:35 – 10:50am	Reporting of a positive multi-center phase III trial of SRS vs. HA-WBRT	Ayal Aizer, MD, MHS
10:50 – 11:05am	NCI NCORP update	Brandy Heckman-Stoddard PhD, MPH
11:05 – 11:20am	NCI CCDR update	Rachelle Brick, PhD, Program Director/NCORP CCDR Project Scientist, NCI Health Care Delivery Research Program
11:20 – 11:30am	Questions/discussion	

Protocol Support Committee

Protocol Spotlights

Friday, July 25, 2025
10:30 am - 11:45 am ET

In-person & Virtual

Nurse / Clinical Research Associate
Continuing Educational Sessions

PROGRAM FACILITATORS

Cynthia Licavoli, RN, BSN, MHA

Marissa Weiss, MBA

Jacqueline Ludwig, RN, BSN, CCRP

AGENDA

Introduction

Cynthia Licavoli RN, BSN, MHA

Jacqueline Ludwig, RN, BSN, CCRP

NRG-CC015

Julienne Bower, PhD

NRG-GY036

Ying Liu, MD, MPH

NRG-BR009

Shannon Puhalla, MD

Wrap-Up / Evaluations

This activity has been approved by the Virginia Nurses Association to award contact hours.

The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Session Title	PSC Nurse/CRA- Continuing Education Session- Protocol Spotlights		
Date	07/25/2025	Chair(s)	Cynthia Licavoli, RN, BSN, MHA
Time	10:30 am- 11:45 am ET	Vice Chair(s)	Marissa Weiss, MBA & Jacqueline Ludwig, RN, BSN, CCRP

Meeting Agenda

Time	Topic	Presenter
1030 am-1035am	Introduction	Cynthia Licavoli, RN, BSN, MHA
1035am-1055am	NRG CC015	Julienne Bower, PHD
1055am-1115am	NRG GY036	Ying Liu, MD, MPH
1115 am-1135am	NRG BR009	Shannon Puhalla, MD
1135am-1145am	Wrap Up/Evaluations	Jacqueline Ludwig, RN, BSN, CCRP

Additional Notes: *This activity has been approved by the Virginia Nurses Association to award contact hours. The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.*

General Session

Friday, July 25, 2025
12-1 pm ET



2025 SUMMER MEETING
WASHINGTON DC

#NRG2025



Robert Mannel, MD

Quynh-Thu Le, MD

Norman Wolmark, MD

Presenters

Welcome, Group Updates,
& Highlights

Robert Mannel, MD

NRG Oncology Group Chair



NRG Research Center Update

Mitchell Machtay, MD

NRG Oncology Deputy Group Chair



NRG Statistics & Data
Management Center (SDMC)
Update

James Dignam, PhD

NRG Oncology Group Statistician



NRG NCORP Research Base Update

Deborah Watkins Bruner, RN, PhD

NRG NCORP PI



Session Title	General Session		
Date	July 25, 2025	Chair(s)	Robert Mannel, MD, Quynh-Thu Le, MD, Norman Wolmark, MD
Time	12:00 – 1:00pm ET	Program Facilitator	Robert Mannel, MD

Meeting Agenda

Time	Topic	Presenter
12:00 – 12:20pm	Welcome, Group Updates, and Highlights	Robert Mannel, MD, NRG Oncology Group Chair
12:20 – 12:30pm	NRG Research Center Update	Mitchell Machtay, MD, NRG Oncology Deputy Group Chair
12:30 – 12:40pm	NRG Statistics and Data Management Center (SDMC) Update	James Dignam, PhD, NRG Oncology Group Statistician
12:40 – 12:50pm	NRG NCORP Research Base Update	Deborah Watkins Bruner, RN, PhD, NRG NCORP PI
12:50 – 1:00pm	Questions & Closing Remarks	Robert Mannel, MD, NRG Oncology Group Chair

Scientific Session

Best of NRG Oncology "Present-o-Rama"

Friday, July 25, 2025
3-4:30 pm ET



2025 SUMMER MEETING
WASHINGTON DC

#NRG2025

Practice Changing Evidence Across the Spectrum of Cancer Care

Session 1: Phase III Trials That Shape Clinical Practice



Moderated by
Robert Mannel, MD
Stephenson Cancer Center

NRG-BR003



Vicente Valero, MD
MD Anderson Cancer Center

GOG-0264



Jubilee Brown, MD
Atrium Health

RTOG 1112



Laura Dawson, MD
University of Toronto

Session 2: Less is More: Surgical De-escalation & Patient-Centered Outcomes



Moderated by
Angeles Alvarez Secord, MD, MHSc
Duke Cancer Institute

NSABP B-35



Irene Wapnir, MD
Stanford University

GOG-0278



Allen Covens, MD
Sunnybrook Research Institute

Session 3: Innovation & Insights from NRG Trials



Moderated by
Mitchell Machtay, MD
Penn State Cancer Institute

RTOG 1308



David Qian, MD
MD Anderson Cancer Center

RTOG 0126



Alan Dal Pra, MD
University of Miami

RTOG 9512



Neil Hayes, MD
University of Tennessee

RTOG 9202



Paul Nguyen, MD
Dana-Farber Cancer Institute

NRG-GY017



Jyoti Mayadev, MD
University of California, San Diego

Session Title	Scientific Session – <i>Best of NRG Oncology “Present-o-Rama”: Practice-Changing Evidence Across the Spectrum of Cancer Care</i>		
Session Chairs	Robert Mannel, MD, Angeles Alvarez Secord, MD, MHSc, Mitchell Machtay, MD, James Dignam, PhD		
Date	July 25, 2025	Time	3:00 – 4:30pm ET

Learning Objectives

Following this activity, participants will be better able to:

- 1. Translate Phase III Trial Findings into Clinical Practice**
 - Evaluate recent NRG Oncology phase III trials that have the potential to change standards of care in breast cancer, gynecologic cancers, and hepatocellular carcinoma.
 - Discuss how trial outcomes inform treatment planning, particularly in high-risk or hard-to-treat populations.
- 2. Integrate Emerging Technologies and Biomarkers into Oncology Research**
 - Explore how artificial intelligence, digital pathology, and gene signatures are being validated to predict treatment benefit.
 - Assess the role of translational endpoints in advancing precision medicine strategies across multiple cancer types.
- 3. Assess Approaches to Surgical and Radiation De-escalation**
 - Review evidence from trials investigating reduced-intensity or less extensive surgical interventions and their impact on patient-centered outcomes.
 - Discuss how margin width, organ preservation, and quality-of-life considerations factor into de-escalation decisions.
- 4. Encourage Innovation Through Early Career and Ancillary Studies**
 - Highlight contributions from early-career investigators driving innovation in radiation techniques, dosimetry, and supportive care.
 - Examine how ancillary and dosimetric studies enrich our understanding of treatment toxicity and immune effects.
- 5. Foster Multidisciplinary Interpretation and Implementation of Research**
 - Synthesize insights across trials and disciplines to guide practical changes in oncology care.
 - Engage in collaborative discussions on how new evidence should influence clinical guidelines and future research priorities.

Meeting Agenda

Time	Topic	Presenter
3:00 – 3:05pm	Welcome & Introduction	Robert Mannel, MD <i>Stephenson Cancer Center</i>
3:05 – 3:20pm	Session 1: Phase III Trials That Shape Clinical Practice <i>Moderated by Robert Mannel, MD</i>	
	NRG-BR003 – Adjuvant doxorubicin-based chemotherapy in triple-negative breast cancer	Vicente Valero, MD <i>MD Anderson Cancer Center</i>
	GOG-0264 – Chemotherapy for newly diagnosed and recurrent Chemo-naïve stromal ovarian tumors	Jubilee Brown, MD <i>Atrium Health</i>
	RTOG 1112 – Stereotactic body radiotherapy + sorafenib vs sorafenib alone in hepatocellular carcinoma	Laura A. Dawson, MD <i>University of Toronto</i>
3:20 – 3:30pm	Session 2: Less is More: Surgical De-escalation & Patient-Centered Outcomes <i>Moderated by Angeles Alvarez Secord, MD, MHSc</i>	
	NSABP B-35 – Margin width & local recurrence in NRG/NSABP B-35 DCIS lumpectomy trial	Irene L. Wapnir, MD <i>Stanford University</i>
	GOG-0278 – Efficacy, fertility, and quality of life and cognitive function post-surgery in cervical cancer	Allan Covens, MD <i>Sunnybrook Research Inst.</i>
3:30 – 3:45pm	Panel Discussion/QA for Session 1 & 2	All Speakers & Moderators
3:45 – 4:10pm	Session 3: Innovation and Insights from NRG Trials <i>Moderated by Mitchell Machtay, MD</i>	
	RTOG 1308 – Proton vs. photon RT: Dosimetry to immune system and OARs in lung cancer: Analysis of NRG/RTOG 1308	David Qian, MD, PhD <i>MD Anderson Cancer Center</i>
	RTOG 0126 – Dose-escalated vs. standard-dose RT in prostate cancer: Validation of a predictive gene signature	Alan Dal Pra, MD <i>University of Miami</i>
	RTOG 9512 – Hyperfractionated vs. standard RT in glottic carcinoma: Gene mutations predictive of local failure	Quynh-Thu Le, MD <i>Stanford University</i>
	RTOG 9202 – An AI digital pathology predictive biomarker in locally advanced prostate cancer treated with RT + androgen suppression.	Paul Nguyen, MD <i>Dana-Farber Cancer Inst.</i>
	NRG-GY017 - Atezolizumab with chemoradiation in locally advanced cervical cancer	Jyoti Mayadev, MD <i>University of CA – San Diego</i>
4:10 – 4:30pm	Panel Discussion/Q&A for Session 3	All Speakers & Moderators

Communications & Digital Engagement Workshop



formerly Social Media Workshop

Monday, July 21, 2025
1-2pm ET




2025 SUMMER MEETING
WASHINGTON DC

#NRG2025

Session Co-Chairs



Kristin Higgins, MD
City of Hope



Miriam Knoll, MD, DABR
Northwell Health

Presenters

**Recording available
after NRG Meeting.**



Ryan Strandlund
Associate Director, Grassroots Advocacy
for Cancer Professionals
ASCO

Driving Policy, Improving Care: Digital Advocacy for Cancer Professionals



Sara Rothschild, MPH
Executive Director
The Life Raft Group

The Life Raft Group – Advocacy for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases



Patricia Ganz, MD
UCLA / Jonsson Comprehensive Cancer Center
NRG-CC015 Protocol Co-Chair

NRG-CC015: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer – HEAL-ABC
A study to examine mindfulness training to improve mental health and well-being in younger breast cancer survivors



NRG *Oncology*

2025 SUMMER MEETING
WASHINGTON DC

NRG ONCOLOGY

CME/Non-CME Agendas

#NRG2025

Session Title	NRG Adaptive RT Working Group Meeting Agenda		
Date	July 24, 2025	Chair(s)	Hyun Kim, MD
Time	2:00 – 3:00 pm ET	Vice Chair(s)	Adam Yock, PhD
Room Location	Marriott Marquis Hotel – Washington, DC (In Person Only – No A/V, Bring Laptops)		

Meeting Agenda

Time	Topic	Presenter
2:00 – 2:10pm	Welcome, Introductions <ul style="list-style-type: none"> Working Group Updates Held zoom meetings - Sept. 19th, Nov. 21st and May 15th <u>Industry Roundtable (Closed Meeting)</u> In person meeting with interested industry partners (Varian, Elekta, RayStation, Mevion, Reflexion, Accuray, MIM, United Health Imaging) Discuss how we can collaborate and give input on how they drive their technology 	Hyun Kim, MD Adam Yock, PhD
2:10 – 2:15pm	<u>Goals/Objectives</u> <ul style="list-style-type: none"> Clinical focus Generate adaptive RT protocol templates Resource for developing clinical trials / Pls Disease Site Representatives 	Hyun Kim, MD Adam Yock, PhD
2:15 – 2:20pm	Update/Review of Adaptive RT Template Components	Hyun Kim, MD Adam Yock, PhD
2:20 – 2:25pm	<ul style="list-style-type: none"> Imaging Committee IROC Heme 	Karthik Sundaram, Dave Fuller Michael Knopp Austin Sim
2:25 – 2:55pm	<u>Disease Sites</u> <ul style="list-style-type: none"> GYN GU <ul style="list-style-type: none"> -Bladder trial – ARCHER GU015 CNS Lung H & N Breast GI – Colorectal GI – Non-Colorectal <ul style="list-style-type: none"> GI011 HCC trial –GI012) Sarcoma 	Kevin Alburquerque, Scott Glaser Himanshu Nagar/ Rojano Kashani / Luca Valle Rupesh Kotecha / Christina Tsien Pamela Samson / Michael Weldon Nancy Lee / Sharon Spencer Hunter Boggs / Rebecca Shulman Hyun Kim /Nina Sanford/Michael Chuong / Lauren Henke Mehran Yusuf / James Tsui
2:55 – 3:00pm	Other Business: Questions/ General Discussions	All

Additional Notes:

NEXT ZOOM MEETING - Zoom meetings for this WG would be 2 x's between July 2025 and January 2026.

- Every other month for 1 hr. (Sept. 18th and Nov. 20, 2025) on the 3rd Thursday
- 3:00 PM Eastern Time / 2:00 PM Central Time / 12 pm Pacific Time

Next NRG Meeting: January 22-24, 2026 - Hilton San Francisco Union Square in San Francisco, CA

Breast Cancer Workshop Agenda

Date: July 26, 2025
Start and End Time: 9:00 am – 12:00 pm
Chair: Eleftherios Mamounas, MD
Co-Chairs: Julia White, MD; Charles Geyer, MD; Mothaffar Rimawi, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Identify and describe the design and status of new breast cancer clinical trials.
2. Identify and describe the status of ongoing breast cancer clinical trials.
3. Identify and describe new forms of radiotherapy delivery and their use in breast cancer trials.
4. Identify and describe systemic therapies, including chemotherapeutic drugs, hormonal strategies, biologic agents, new classes of targeted therapies, and immunotherapy that may be used in breast cancer treatment clinical trials.

WORKSHOP AGENDA

9:00 – 9:45	Report from the Breast Working Group Meeting	Eleftherios Mamounas, MD Julia White, MD
9:45 – 10:00	BR003: A Randomized Phase III Trial Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node Positive or High-Risk Node Negative TNBC	Vicente Valero, MD
10:00 – 10:30	BR008: A Phase III Randomized Trial Evaluating Omission of Breast Radiotherapy for Low-Risk HER2-Positive Breast Cancer	Lior Braunstein, MD Melissa Mitchell, MD, PhD
10:30 – 11:00	BR009: Chemotherapy plus ET vs. Ovarian Ablation plus ET in Early-Stage Hormone-Positive Premenopausal Women with Oncotype < 25 (OFSET CHEMO)	Sandra Swain, MD Shannon Puhalla, MD Eleftherios Mamounas, MD
11:00– 11:15	BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Breast Cancer with a Low Oncotype Recurrence Score	Julia White, MD
11:15 – 11:30	Phase III Randomized Trial: Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)	Rachel Rabinovitch, MD Wendy Woodward, MD, PhD
11:30 – 12:00	Discussion	

Session Title	NRG Canadian Subcommittee Meeting		
Date	July 24, 2025	Chair(s)	Al Covens, MD
Time	11:00am – 12:00pmET	Vice Chair(s)	Christina Tsien, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss the status and significance of new and ongoing NRG Oncology clinical trials available in Canada
2. Discuss and subsequently apply standards and procedures required to participate in a research protocol supported by NRG Oncology
3. Learn about trials available in Canada

Meeting Agenda

Time	Topic	Presenter
11:00 – 11:05am	Welcome, Introductions	Al Covens, MD; Christina Tsien, MD
11:05 – 11:15am	Comments/questions for NRG Group Chairs	Quynh-Thu Le, MD
11:15 – 11:20am	QA Audit update	Mary Jo Antonelli
11:20 – 11:25am	Upcoming/ongoing trials in Canada	Erica Field
11:25 – 11:35am	NRG Genitourinary (GU) committee updates	Paul Nguyen, MD, NRG Genitourinary Committee Chair
11:35 – 11:45am	NRG Head and Neck committee updates	Sue Yom, MD, NRG Head and Neck Committee Chair
11:45am – 12:00pm	Q&A/Discussion	

Session Title	NRG CCDR Committee Meeting		
Date:	July 24, 2025	Chair(s)	Mary Cooley, PhD
Time	12:00 – 1:30pm	Vice Chair(s)	Sarah Hawley, PhD

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss proposed and ongoing NRG cancer care delivery research trials.
2. Identify and prioritize areas of unmet need in cancer care delivery research.
3. Apply procedures required to design, submit and implement a research protocol for support by the NRG.

Meeting Agenda

Time	Topic	Presenter
12:00 – 12:10pm	NRG CCDR announcement and updates	Mary Cooley, PhD
12:10 – 12:25pm	NRG-CC012CD study update	Tracy Crane, PhD
12:25 – 12:40pm	Connected Care Transitions in Breast cancer survivors	Sarah Hawley, PhD
12:40 – 12:45pm	Q&A/Discussion	
12:45 – 1:00pm	Concept discussion: Implementing a prostate cancer decision aid in NCORP practices	Ronald Chen, MD
1:00 – 1:15pm	Expanded access surveillance paradigm in HPV mediated oropharyngeal squamous cell carcinoma	Molly Heft-Neal, MD
1:15 – 1:30pm	Q&A/Discussion	

Session Title	Cancer Prevention and Control Committee Meeting		
Date	July 24, 2025	Chair(s)	Julie Bauman, MD; Tracy Crane, PhD
Time	1:45 – 3:15pm ET	Vice Chair(s)	Stephanie Blank, MD; Mylin Torres, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss ongoing and proposed NRG clinical trials on cancer prevention and control.
2. Discuss strategies for recruitment, retention and enrollment.
3. Discuss multi-disciplinary aspects of ongoing and proposed clinical trials in each of the primary disease sites.

Meeting Agenda

Time	Topic	Presenter
1:45 – 2:00pm	Welcome CPC trial updates	NRG CPC Chairs
2:00 – 2:10pm	NRG-CC013: Trial update	Sue Yom, MD
2:10 – 2:25pm	NRG-CC016: Phase III Randomized Trial: Assessment of Biosignature Classification for DCIS Radiotherapy Benefit Post Lumpectomy (ABCD RT)	Rachel Rabinovitch, MD
2:25 – 2:40pm	NRG-CC017: Randomized Ph III Study Comparing Temporally Modulated Pulsed Radiation Therapy (TMPRT) vs Standard Radiation Therapy with Temozolomide for Adults with Newly Diagnosed MGMT-Unmethylated Glioblastoma	Jiayi Huang, MD
2:40 – 2:50pm	Q&A/discussion	
2:50 – 3:05pm	Developing concept: Seamless Randomized Phase II/III Trial of Reduced-Dose versus Standard-Dose Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT)	Melin Khandekar, MD
3:05 – 3:20pm	Developing concept: Celiac Plexus Radiosurgery for Pain Management – A Randomized Trial	Yaacov Lawrence, MD
3:20 – 3:35pm	Pilot project update: Helicobacter pylori eradication for primary prevention of gastric cancer	Shria Kumar, MD
3:35 – 3:45pm	Q&A/discussion	

Session Title	Cervical and Vulvar Cancer Subcommittee Meeting		
Date	July 25, 2025	Chair(s)	Charles A. Leath, III
Time	8:00 – 10:00 am EDT	Vice Chair(s)	Jyoti Mayadev; Dmitry Zamarin

Learning Objectives

Following this activity, participants will be better able to:

1. Review recent knowledge gained in treating cervical cancer
2. Discuss organization, planning and completion of the GCIG Consensus Conference
3. Reviewed current gaps in NCI cervical cancer portfolio and ways to address

Meeting Agenda

Time	Topic		Presenter
8:00 – 8:15	Introduction / Announcements		Leath, Mayadev, Boyd, Williams
	<ul style="list-style-type: none">a. Welcome, committee membership and rotation plan and review of January 2025 minutes<ul style="list-style-type: none">i. Annual rotation of approximately 10% from CORE committeeb. New NCORP Liaison – Dr. Kathryn Millsc. Cervix updates from the task forces/Patient Advocate<ul style="list-style-type: none">i. Cervical Cancer Task Force – Leslie Boydd. Cervical cancer patient advocate – Kimberly Williams		
8:15 – 8:45	A. Educational Session <ul style="list-style-type: none">a. Christian Hinrichs – Cell Therapies for HPV-associated cancersb. Charles Kunos – Radiopharmaceuticals for Gynecologic Cancers		Hinrichs, Kunos
8:45 – 9:50	B. New Concepts		(continued)
	CV2435 A Phase II Randomized Trial of Chemotherapy ± Pembrolizumab in Recurrent Cervial Cancer After Prior Chemoradiation and Pembrolizumab (RECAP-Cx) (Gien) CV, GYN, IO		
	Hinrichs	Christian ch977@cinj.rutgers.edu	
	Miller	Katherine kamiller@wihri.org	
	CV2538 Personalized ctDNA Response to Determine Immunotherapy Continuation in Locally Advanced Cervical Cancer. (Rash, Washington, Monk, Mayadev) CV, GYN, IO		
	Doll	Corinne Corinne.Doll@albertahealthservices.ca	

Olawaiye Alexander olawaiyea@mail.magee.edu

DT2530 A Phase II Study of Sacituzumab Govitecan in Recurrent or Metastatic Vulvar Cancer. (Chambers, Backes)

Pfaendler Krista krista.pfaendler@hsc.wvu.edu

Salani

DT2534 Single-arm Phase II alpha-particle study of [^{203/212}Pb]Pb-PSV-359 monotherapy in patients with Persistent, recurrent or metastatic Uterine Cervix Cancer that are known to be fibroblast activation protein (FAP)-Positive. (Fabian, Kunos) **DT, CV, GYN**

Ayala-Peacock Diandra N. Diandra.ayalapeacock@duke.edu

Barry Parul barrypn@upmc.edu

Operational management on-going NRG trials

C. Closed Studies

Protocols: 101, 120, 205, 222, 141, 173, 179, 204, 206, 240, 233, 279, 9806

D. Active / Recently Completed Trials

- a. **NRG-GY024** Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (Slomovitz) N=157
 - i. Opened April 2021
 - ii. NRG Accrual 15
- b. **GOG-0724/RTOG0724**: Phase III trial randomized study of concurrent chemotherapy and pelvic RT with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy. (Heidi Gray, Anuja Jhingran)
 - i. Opened April 2009
 - ii. ASCO Presentation 2024
 - iii. Manuscript to co-authors?
- c. **GOG-0263**: Randomized clinical trial for adjuvant chemoradiation in post-operative cervical cancer patients with intermediate risk factors (Sang Young Ryu, Kevin A)
 - i. Opened April 2010
 - ii. Amended Nov 2017 to decrease accrual from 534 to 360
 - iii. Closed to Accrual – 339/360 (94.2%)
 - iv. SGO Presentation 2025
 - v. Manuscript submitted to *Annals of Oncology*
 - vi. QOL Manuscript in Preparation

9:55 – 10:00

- d. **GOG-0278:** Evaluation of physical function and quality of life (QOL) before and after non-radical surgical therapy for stage IA1-IB1 (≤ 2 cm) cervical cancer. (Al Covens)
 - i. Opened October 1, 2012
 - ii. SGO Presentation 2024
 - iii. Published *Gynecologic Oncology*
- e. **GOG-0279:** A phase II trial evaluating cisplatin and gemcitabine concurrently with intensity-modulated radiation therapy (IMRT) for the treatment of locally advanced squamous cell carcinoma of the vulva. (Neil S. Horowitz)
 - i. Opened July 2, 2012
 - ii. Temporarily Closed June 15, 2015 after enrolling 28 in 1st stage
 - iii. 2nd stage re-opened July 2016
 - iv. Published *Journal of Clinical Oncology*
To be terminated
- f. **NRG-GY006:** A randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, stage II, IIIB, or IVA Cancer of the uterine cervix or Stage II-IVA vaginal cancer. (Trey Leath, Loren Mell)
 - i. Opened January 15, 2016
 - ii. Amendment to CTEP re: increase in accrual size and transition to Randomized phase 3
 - iii. Temporarily closed secondary to drug shortage May 28, 2021
 - iv. Accrual complete
 - v. Published *Gynecologic Oncology*
 - vi. Ongoing PET/CT analyses
- g. **NRG-GY017:** Phase I trial using anti PD-L1 (atezolizumab) as immune primer and concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer. (Jyoti Mayadev)
 - i. Opened October 26, 2018
 - ii. Accrual: 40/40
 - iii. Presentation SGO 2022 and SGO 2023; final analysis report to be performed Oct 2022
 - iv. Published *Nature Communications Jan 2025*

E. Previously Rejected Concepts

- a. Committee Level
 - v. CONTESSA (Cobb) – Fertility sparing surgery
 - vi. CERVANTES (GCIG) – Follow-up to Sedlis with radical surgery and adjuvant therapy
 - vii. CV1948 – Radical hysterectomy via LSC vs. Xlap (Davidson)
 - viii. CV2062 (Wiebe) – PROS – not approved based on design
 - ix. CV2133 (Mayadev / Mell) – Durvalumab in place of CDDP for platinum ineligible patients
 - x. CV2226 (Frumovitz) – PAROLA – PA lymphadenectomy study

- xi. KGOG 1047 (Roh) – Debulking lymphadenectomy study
- xii. CV2333 (Rose) – A18 Replacement
- xiii. CV2407 (Lea/Miller) – A Phase III randomized three arm trial of concurrent chemoradiation or pembrolizumab and concurrent chemoradiation or induction chemotherapy followed by concurrent chemoradiation in locally advanced cervical cancer – Lea moved to NRG-GY037 study team PI

b. GCSC Level

- xiv. CV1963 - Randomized Phase II Trial of Ablative Radiation Therapy for Women with Oligometastatic Recurrent Cervical Cancer (Taunk/Chino)
- xv. CV2220 - A Randomized Phase II Study of the Integration of Hypofractionated Image-Guided Pelvic Radiotherapy Into Chemotherapy and Pembrolizumab/Bevacizumab in Newly Diagnosed Stage IVB Cervical Cancer Stage IVB ChemoRT (D. Chase)
- xvi. CV2040 (Leung) – SPARTACUS II
- xvii. PI1915 (Moxley) – PARP+ATR – Not supported by CTEP.
- xviii. PI2136 (Moxley) – PARP+ATR – Not supported by CTEP/Drug Sponsor
- xix. **CV2432 (Washington) – T-DXd vs. TV - Accrual and Current supportive data primarily**

DT2430 (Musa) - **DT2430** Dual mTOR and Immune Checkpoint Inhibition as a Strategy for Recurrent Cervical Cancer (TORIC): A Phase I/II study of sapanisertib plus pembrolizumab (Fernanda Musa, Katy Moore) CRDL

c. Other

- xx. CV1912 (Lin) – Nelfinavir+CRT for locally advanced vulvar cancer – Not on CRADA
- xxi. DT2013 (Doll) – Glutaminase inhibitor with CRT for node positive LACC – Compound abandoned by sponsor
- xxii. CV1922 (Salani) – Maintenance strategies after GOG 240 Therap. Not supported by Pharma.
- xxiii. DT2059 (Henson) Hypofractionated RT with M3814 and avelumab – Agent abandoned by company
- xxiv. CV2143 (Salani) – Substitution of TV for paclitaxel with Platinum, Pembrolizumab a+/- bevacizumab – TV not on CRADA and not supported
- xxv. CV2218 (Salani) – Addition of Tiragolumab and Atezo vs. Physician's choice chemotherapy

F. Reports from Other Committees and Groups

- a. Publications Subcommittee
- b. Patient Centered Outcomes Research Committee
- c. Ancillary Data Committee
- d. Cancer Prevention and Control
- e. Rare Tumor Committee
- f. Vaccine Subcommittee

- g. Pathology Committee
- h. Radiation Committee
- i. SPORE Committee
- j. Nursing
- k. Medical Oncology
- l. Patient/Community/Advocacy

Concluding Remarks and Wrap-up

Additional Notes:

- 1. Interim Remote Meeting – Likely October 10, 2025 for Core committee members**
- 2. Winter 2026 Meeting – January 22-24, 2026, Hilton San Francisco Union Square**

Session Title

Developmental Therapeutics Committee

Date

Thursday July 24, 2025

Chair(s)

Roisin O’Cearbhaill, MD (Dev. Therapeutics)

Panagiotis Konstantinopoulos (Dev. Therapeutics /
Translational Research Chair)

Stephanie Gaillard, MD, PhD (Phase I)

Time

12:30 – 2:30pm

Vice Chair(s)

Bradley Corr, MD (Phase I)

Floor Backes, MD (Phase II)

Learning Objectives

Following this activity, participants will be better able to:

1. Participants will become familiar with the current status of translational research projects involving phase I and II studies that are under development or activated for accrual.
2. Participants will become familiar with current CTEP assets available for study
3. Clinical data related to novel investigational agents will be reviewed.
4. Recommendations for action by the GYN Developmental Therapeutics committee will be summarized.

Meeting Agenda

Time	Topic	Presenter
12:30 – 12:35	Introduction , Welcome. Review of opportunities for new investigators and discuss committee rotation.	Drs. O’Cearbhaill, Gaillard, Corr, Backes, Konstantinopoulos
12:35 – 2:00	Review DT new concepts DT2529 Phase II Study of Single-agent Pembrolizumab (anti PD-1) in dMMR Early Stage Endometrial Cancer Patients Desiring Fertility Preservation (Covens, Spenard, Swift)	Reviewers Oladapo Yeku, Dmitriy Zamarin, Ira Winer
	DT2530 A Phase II Study of Sacituzumab Govitecan in Recurrent or Metastatic Vulvar Cancer. (Chambers, Backes)	Eugenia Girda, Debra Richardson, Kristen Zeligs
	DT2534 Single-arm Phase II alpha-particle study of [^{203/212} Pb]Pb-PSV-359 monotherapy in patients with Persistent, recurrent or metastatic Uterine Cervix Cancer that are known to be fibroblast activation protein (FAP)-Positive. (Fabian, Kunos)	Karen McLean, Jyoti Mayadev, Chrisann Kyi

Review for other committees:

UC2531: A randomized phase II trial of Sacituzumab Govitecan with bevacizumab with or without zimberelimab in patients with advanced previously treated endometrial cancer (Holtzman/Zamarin) – safety lead in.

June Hou, Lee-May Chen,
Sarah Taylor

Presentation of open active studies (see list of studies below)

GY022, GY031, ComboMATCH (EAY191-N4, EAY191-N4, EAY191-A3, EAY191-S3)

Update on studies under development:

NRG-GY034 A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel with or without Bevacizumab in Patients with Recurrent Epithelial Ovarian Cancer (Zeligs/Annunziata/Moore) n=88

- **Disapproved** – drug no longer being developed

DT2430 Dual mTOR and Immune Checkpoint Inhibition as a Strategy for Recurrent Cervical Cancer (TORIC): A Phase I/II study of sapanisertib plus pembrolizumab (Musa/Moore)

- **Disapproved by CTEP 4/14/25 based on:**

- 1) The use of pembrolizumab in combination with sapanisertib in this disease setting is not well justified. Nearly all patients with recurrent or metastatic cervical cancer will have received ICI prior to meeting eligibility for this proposed study.
- 2) There is no provided data to support ICI rechallenge/re-expose in patients with cervical cancer.

UC2511 Phase II Trial of Weekly Paclitaxel With and Without Inavolisib in Recurrent Endometrial Cancer (Kristin Taylor/Rimel) N=96

- Next step UTF review in fall

DT2418 A Preoperative Window Study of Pembrolizumab with or without Uterine-Directed Radiation Therapy for NSMP High Risk Resectable Endometrial Cancer (Harkenrider/Duska) N=50

- RSC approved (6/23/25)
- Preparing for LOI submission to CTEP
- May have to go to Biomarker Review Committee depending upon final endpoint

2:00 – 2:20

2:20 – 2:30

Open discussion, closing remarks.

Additional Notes:

List of Studies

Active PK Studies:

- **NRG-GY022**, Assessment of carboplatin clearance predictors: a companion PK study to NCI sponsored clinical trials or standard of care treatments using carboplatin (Sarah Taylor/Jan Beumer)
 - **305/350 enrolled**
 - **Open up to male participants only now**
 - **Video available to improve enrollment.**

Active Phase I Studies:

- **NRG-GY031** A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer (Andriani/Simpkins).
 - **Opened 8/31/23 ; 13/60 enrolled**
 - **Photophobia** – nighttime dosing in 2nd week of treatment, naps after dosing, sunglasses
 - **n/v:** Zofran prophylaxis 30 min prior (consider dex, olanzapine, rolapitant)
 - **Careful with prior severe myelosuppression**
 - **Still on hold. Amendment pending**

Safety lead-in

- **NRG-GY025** A randomized phase II trial of immunotherapy with dual immune checkpoint inhibitors compared to antiPD1 monotherapy in patients with deficient mismatch repair system recurrent endometrial carcinoma (Mahdi) – **currently open to all sites**
 - **42/81 patients enrolled (2nd safety lead-in: 25 in combo arm)**
 - Safety call every other Friday 3:00 pm
 - Measurable or evaluable disease; 0-2 prior lines (allowed to be chemo naïve)

Active Phase II Studies (including safety lead-ins):

- **EA191- N4** A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial (Westin)
 - **Opened 3/6/23; 104/165 enrolled**
 - Assess for fatigue early, taking interruption and dose reduction sooner rather than later
 - Steroid and antibiotic creams on hand before rash starts. Intervene early (at grade 1) to avoid serious rashes.
 - Toxicity check per phone – 1-2 weeks in (4 week cycle)
 - Mandatory biopsy needed
- **EAY191-N5** A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial (Mahdi)
 - **Opened 2/12/24; enrolled 17/70**
 - Plan to amend the protocol to allow prior ADC and other HER2 targeting (emailed Haider 12/6/24)

- **EAU191-A3:** Palbociclib and Binimetinib in RAS-Mutant Cancers (Shapiro and Liu)
 - Opened 11/15/2023
 - Current accrual 44/199
 - Includes low grade serous ovarian cancer
 - Registration to Cohort 1 is Closed to Accrual as of 04/01/2025
 - Registration to Cohort 4 is Temporarily Closed to Accrual as of 09/05/2024
 - Registration to Cohort 3 is Temporarily Closed to Accrual as of 07/03/2024
- **EAY191-S3:** Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial (Basho)
 - Opened 3/6/2023
 - Current accrual 22/33

Closed DT/Phase I studies:

Cervical Cancer Studies:

- **NRG-GY017** Anti PD-L1 (atezolizumab) as an immune primer and concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer (Mayadev/ Schilder/Zamarin)
 - Plenary at SGO 2022 and 2023
 - Manuscript status update

Endometrial Cancer Studies:

- **NRG-GY014**, A phase II study of tazemetostat (EPZ-6438) in recurrent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma (Eskander)
 - Presented at SGO 2024
 - Awaiting manuscript
- **GY028 (PTMA #100828)** Phase IB and randomized phase II trial of medroxyprogesterone acetate +/- ipatasertib in recurrent/metastatic endometrioid endometrial cancer (Onstad Grinsfelder/Westin)
 - Opened 1/13/23 ; Completed phase Ib
 - Reopened to phase II – now under Corpus committee
 - Completed accrual 6/2025

Ovarian Cancer Studies:

- **NRG-GY007** A phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (Landen) Completed accrual.
 - Presented at ASCO 2022, Published JCO Jul 2024.
- **NRG-GY009 (PTMA/CRDL)** A randomized, phase II/III study of pegylated liposomal doxorubicin and atezolizumab versus pegylated liposomal doxorubicin/bevacizumab and atezolizumab versus pegylated liposomal doxorubicin/bevacizumab in platinum resistant ovarian cancer (O'Cearbhaill)
 - Phase II completed accrual May 2019. Phase III completed accrual October 2021
 - IGCS 2023
- **NRG-GY021** A randomized phase II trial of olaparib versus olaparib + tremelimumab in platinum-sensitive recurrent ovarian cancer (Adams)

- Safety lead-in closed March 2021, study permanently closed
 - Toxicity limited further enrollment and analyzing data, manuscript pending
 - CMAC is doing correlative studies and completed.
- **GY027** Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Carboplatin and Paclitaxel with Ipatasertib in Epithelial Ovarian Cancer (Fuh/Moore)
 - Completed

Session Title NRG Developmental Therapeutics Radiation Therapy Subcommittee

Date July 21, 2025 **Chair(s)** Steven Lin, MD, PhD

Time 3:00 – 4:30 pm ET **Vice Chair(s)** Sandip Patel, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Understand the importance of lymph nodes and lymphatic channels in anti-tumor immune responses.
2. Identify potential strategies to spare lymphatic structures when using radiation and surgery.

Meeting Agenda

Topic	Presenter
CME Presentation Lymphatic Sparing Neoadjuvant ImmunoRadiation In Head and Neck Cancer	Andrew Sharabi, MD
Disease Site and Subcommittee Updates:	
Brain/CNS (Committee Liaison: Vinay Puduvalli, MD)	Vinay Puduvalli, MD
Genitourinary (Committee Liaison: Zachary Zumsteg, MD)	Zachary Zumsteg, MD
Head and Neck	Sandip Patel, MD
Lung (Committee Liaison: Steven Lin, MD, PhD)	Steven Lin, MD, PhD
GI (non-colorectal and colorectal) (Committee Liaison: Terence Williams, MD)	Terence Williams, MD
GYN (Committee Liaison: Jyoti Mayadev, MD)	Jyoti Mayadev, MD
Breast (Committee liaison: Steve Chmura, MD)	Steve Chmura, MD
Sarcoma Subcommittee (Subcommittee Liaison: Meng Welliver, MD)	Meng Welliver, MD

Gastrointestinal Cancer Committee Workshop Agenda

Date: Saturday, July 26, 2025
Start and End Time: 11:00 am - 12:30 pm EST
Colorectal Chair: Thomas George, MD, FACP, FASCO
Colorectal Co-Chair: Scott Kopetz, MD, PhD, FASCO
Non-colorectal Chair: Ted Hong, MD
Non-colorectal Co-Chair: David Ilson, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Appreciate the eligibility criteria and hypotheses being explored in current and upcoming GI Onc clinical trials

WORKSHOP

AGENDA

		Discussion/Study Information	Speaker
		Introduction and Opening Remarks, Announcements and Working Group updates	Ted Hong, MD Thomas George, MD
11:00	CRC SUBCOMMITTEE - Review of Active and Select Upcoming NCTN Trials		
NET		NCTN Portfolio of NET Studies	Heloisa Soares, MD
Adj. Colon	NRG-GI008 (CIRCULATE-NA) A021502 (ATOMIC)	ctDNA as decision tool for stage III colon cancer treatment Adjuvant FOLFOX +/- Atezolizumab for stage III dMMR colon cancer - CLOSED	Arvind Dasari, MD
mCRC	NRG-GI004/S1610 (COMMIT) EA2222 A022101/NRG-GI009 (ERASur)	MSI-H mCRC 1L Immunotherapy Study Systemic therapy +/- HAI following 1L therapy Oligo mCRC Total Ablative Therapy	Caio Rocha Lima, MD Motaz Qadan, MD Paul Romesser, MD Kate Hitchcock, MD, PhD Eric Miller, MD, PhD
	NRG-GI013 (RADIO)	Ablative Liver Met Radiation for IO Response in Microsatellite Stable (MSS) mCRC	Aparna Parikh, MD Chris Anker, MD
Rectal	A022104/NRG-GI010 (JANUS) CCTG-032 (NEO-RT)	Watch & Wait vs. TME after optimal TNT Neoadjuvant Chemo, Excision and Observation vs. ChemoRT for Early Rectal Cancer	William Hall, MD Arvind Dasari, MD Noam VanderWalde, MD
11:45	NON-CRC SUBCOMMITTEE - Review of Active Trials and Select Upcoming NCTN Trials		
Liver	NRG GI012 NRG GI003	Atezo/Bev +/- SBRT Phase III RCT of Protons vs. Photons for HCC	Jennifer Wo, MD Ted Hong, MD
EGA	NRG GI006 NRG GI2523 EA2183	Phase III RCT of Protons vs. Photons for Esoph Carcinoma Randomized Trial of OBP-301 (Telomelysin) and Definitive ChemoRT for non-operative locally adv EGA Rand phase II evaluating consolidative radiation + IO during 1L systemic therapy in oligometastatic EGA	Steven Lin, MD Geoff Ku, MD Kimberly Mak, MD
Panc	NRG-GI011 (LAP100) A022106 (PLATINUM)	A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreatic Cancer (LAPC) Patients A phase II/III trial of NABLPAGEM vs nab-paclitaxel/gemcitabine as second-line treatment fore BRCA1/2 or PALB2 mut met PDAC (PLATINUM)	Nina Sanford, MD Raymond Wadlow, MD

Session Title	Genitourinary Cancer Workshop Agenda		
Date	Saturday, July 26, 2025	Chair(s)	Paul Nguyen, MD
Time	7:30 AM – 9:00 AM ET	Vice Chair(s)	Jason Efsthathiou, MD; Todd Morgan, MD; Oliver Sartor, MD, Phuoc Tran MD PhD
Program Facilitators	Paul Nguyen, MD		

Learning Objectives

Following this activity, participants will be better able to:

1. Recognize critical aspects of developing and conducting a clinical trial in genitourinary (GU) cancer therapy research in a cooperative group setting.
2. Identify and describe the design and status of new GU cancer clinical trials being planned and launched by NRG Oncology, to enable contribution to protocol design vetting and/or effective patient enrollment in newly-launched studies.
3. Identify and describe the status of ongoing GU cancer clinical trials being conducted by NRG Oncology, to enable effective patient enrollment in and treatment on these trials, and proper collection, submission and/or evaluation of the required patient data.
4. Identify, describe, and analyze aspects of ongoing NRG Oncology GU clinical trials which are in need of special support and improvement, to enable effective patient enrollment in and treatment on these trials, and proper collection, submission and/or evaluation of the required patient data.
5. Identify and discuss the results and publication status of GU cancer clinical trials recently completed by NRG Oncology, so they can make informed decisions based on the state of the science regarding patient treatment, and they can relay study results to patients treated on these trials.
6. Identify and describe new forms of radiotherapy delivery and their use in NRG Oncology GU cancer trials.
7. Identify and describe systemic therapies, including chemotherapeutic drugs, hormonal strategies, biologic agents, and new classes of targeted therapies that may be used in conjunction with radiation therapy in GU cancer treatment, and the effectiveness of those agents as demonstrated in NRG Oncology clinical trials.
8. Identify and describe new developments in biologic and imaging science that can be used in translational research strategies to identify GU cancer patient subgroups at risk for failure with existing treatments and identify new approaches for these patients.

Meeting Agenda

Time	Topic	Presenter
7:30-7:35	Opening Remarks and Update	Paul Nguyen, MD
7:35 – 8:30	NRG GU008: Androgen Deprivation Therapy With or Without Radiation Therapy or Docetaxel in Patients With Node-Positive Prostate Cancer: A Phase III Randomized Trial	Ronald Chen, MD, MPH

NRG GU009 (PREDICT-RT): Parallel Phase III Randomized Trials for High Risk Prostate Cancer Testing Treatment De-Intensification for Men with Lower Genomic Risk and Treatment Intensification for Men with High Genomic Risk (PREDICT-RT)

Paul Nguyen, MD; Oliver Sartor, MD

NRG GU010 (GUIDANCE): Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-intensification and Intensification Clinical Trial (GUIDANCE)

Neil Desai, MD; Ale Berlin, MD PhD

NRG-GU011: Phase II trial of PROstate oligoMETastatic radiothERapy with or without ANDrogen deprivation therapy (NRG PROMETHEAN)

Bridget Koontz, MD

NRG GU012 (SAMURAI): Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy ("SAMURAI")

Bill Hall, MD
Rana McKay, MD

EA8191: Phase III Study of Local or Systemic Therapy Intensification Directed in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE)

Neha Vapiwala, MD
Bridget Koontz, MD

NRG GU013 (HIGH FIVE): Five fraction radiation for high-risk prostate cancer

Karen Hoffman, MD

NRG-GU014 PAARC: Randomized Phase II Trial Of Pembrolizumab and Radiation vs. Radiation And Concurrent Chemotherapy For High-Grade T1 Bladder Cancer

Scott Delacroix, MD

NRG-GU015 ARCHER: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer

Scott Delacroix, MD
Himanshu Nagar, MD

A031702 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Daniel Spratt, MD

8:30– 9:00

Translational Research

Phuoc Tran, MD PhD

Medical Oncology Update

Oliver Sartor, MD

Urology Update

Todd Morgan, MD

New Business

Group

Additional Notes:

Session Title	Gynecologic Cancer Committee		
Date	July 26, 2025	Chair(s)	Carol Aghajanian, MD
Time	7:45 AM – 9:30 AM	Vice Chair(s)	Paul DiSilvestro, MD David Gaffney, MD, PhD

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss the status and significance of new and ongoing clinical trials on the prevention, diagnosis, and treatment of gynecologic cancers. Discuss priorities for future clinical trials.
2. Apply standards and procedures required to design, submit, and conduct a research protocol for support by NRG Oncology.
3. Assure quality control of gynecologic cancer clinical trials.

Meeting Agenda

Time	Topic	Presenter
7:45 AM–9:30 AM	Future Meetings	Dr. Aghajanian
	Protocol Operations Management (POM) Committee	Dr. DiSilvestro
	Update on Symposia	Dr. Alvarez Secord
	GCIG Report	Drs. Randall & Bookman
	Subcommittee Report: Cervix/Vulvar Cancer Subcommittee	Drs. Leath, Mayadev, Zamarin
	Subcommittee Report: Ovarian Cancer Subcommittee	Drs. Moore, Liu
	Subcommittee Report: Uterine Corpus Cancer Subcommittee	Drs. Powell & Klopp
	Subcommittee Report: Rare Tumor Subcommittee	Drs. Covens & Brown
	Subcommittee Report: Theranostics	Dr. Mayadev
	Developmental Therapeutics (DT) Committee Report	Drs. O’Cearbhaill, Backes, & Konstantinopoulos
	-DT Gynecologic Phase I Subcommittee Report	Drs. Gaillard & Corr
	-DT Sarcoma Subcommittee Report	Dr. O’Cearbhaill
	Cancer Prevention and Control (CPC) Committee Report	Dr. Blank
	Translational Science Committee Report / Translational Science GYN Cancer Working Group	Drs. Birrer & Lankes

Cervix/Vulvar Cancer Subcommittee

New Concepts

- CV2535, Phase II Randomized Trial of Chemotherapy ± Pembrolizumab in Recurrent Cervical Cancer After Prior Chemoradiation and Pembrolizumab (RECAP-Cx) (Lillian Gien)
- CV2538, Personalized ctDNA Response to Determine Immunotherapy Continuation in Locally Advanced Cervical Cancer (Dominique Rash)
- CV2540, A phase II, open-label, randomized trial comparing the efficacy and safety of sacituzumab govitecan monotherapy versus tisotumab vedotin monotherapy in patients with recurrent, metastatic cervical cancer (Krista Pfaendler)
- DT2530, Phase II Study of Sacituzumab Govitecan in Recurrent or Metastatic Vulvar Cancer (Laura Chambers)
- DT2534 Single-arm phase II alpha-particle therapy study of [203/212Pb]Pb-PSV-359 monotherapy in patients with persistent, recurrent or metastatic uterine cervix cancer that are known to be fibroblast activation protein (FAP)-positive (Denise Fabian)

Studies Under Development

- NRG-GY037, A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer (Jyoti Mayadev, Dmitriy Zamarin, Jayanthi Lea, Allison Garda, Tashana Meyers)
- CV2305, Stratification of Vulvar Squamous Cell Carcinoma by HPV And P53 Status To Guide Excision: STRIVE STUDY, CCTG Trial VU.2 (Amy Jamieson, Jessica McAlpine)
- CV2346, Chemoradiation with or without Concurrent and Adjuvant Checkpoint Inhibition in Lymph Node Positive Carcinoma of the Vulva (Scott Glaser)
- CV2512, A phase III non-inferiority trial of hypofractionated chemoradiation therapy versus standard chemoradiation for cervical cancer (Christina Henson)

Active Studies

- NRG-GY024, Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (Brian Slomovitz)

Closed Studies, primary manuscript NOT published: RTOG-0724, GOG-0263

Closed studies, primary manuscript published: 270 (GROINSS-V), NRG-GY006

Biospecimen Access

MP2PRT (Tewari, GOG-0240)

Nav1601/CSC0135 (Secord, GOG-0240)

NRG-GY-TS030/CSC0213 (Mayadev, GOG 9929)

NRG-GY-TS034/CSC0244 (Mayadev, NRG-GY017)

Ovarian Cancer Subcommittee

New Concepts

- OV2532, Randomized phase 3 trial of combination of pembrolizumab with intravenous (IV) or intraperitoneal (IP) chemotherapy followed by pembrolizumab plus olaparib maintenance for patients with HRD negative epithelial ovarian, fallopian tube, and primary peritoneal cancer (Keiichi Fujiwara)
- RT2536, An international phase 3 trial of the efficacy of adjuvant chemotherapy compared to hormonal therapy/surveillance in adult patients with advanced/metastatic or recurrent granulosa cell tumor (GHOST trial) (Lilian T. Gien, MD, MSc, on behalf of Isabelle Ray-Coquard, MD (GINECO))
- RT2537, A Phase II Study of Tissue-Factor (TF) Targeting Antibody-Drug Conjugate (ADC) Tisotumab Vedotin in Gynecologic Clear Cell Carcinomas (Kristen Starbuck)

Studies Under Development

- OV2431, A Phase II trial of sacituzumab govitecan (SG) and bevacizumab versus standard of care carboplatin, liposomal doxorubicin and bevacizumab in patients with platinum-sensitive ovarian cancer that has progressed on prior maintenance PARP inhibitor therapy (Rebecca Porter)
- RT2504, A randomized phase II trial of single vs dual check point inhibitor blockade in recurrent clear cell carcinomas (Cara Matthews)
- RT2519, A Phase II study of ribociclib in combination with letrozole in patients with recurrent adult-type ovarian granulosa cell tumor (Lauren Cobb)

Active Studies

- NRG-GY031, A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer (Fiona Simpkins)
- NRG-GY036, A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (Ying Liu)

Closed Studies, primary manuscript NOT published (Ovarian): NRG-GY009, NRG-GY019, NRG-GY021

Closed Studies, primary manuscript NOT published (DT): NRG-GY014, NRG-GY027

Closed Studies, primary manuscript NOT published (Rare Tumor): NRG-GY033

Closed Studies (primary manuscript published): GOG-0213, GOG-0262, NRG-GY003, NRG-GY004, NRG-GY005, NRG-GY023

Biospecimen Access

NRG-GY-TS022 (Matei, GOG-0136-OV)

NRG-GY003-CSC0255 (Zamarin, NRG-GY003)

Uterine Corpus Cancer Subcommittee

New Concepts

- UC2531, A randomized phase II trial of Sacituzumab Govitecan with bevacizumab with or without zimberelimab in patients with advanced previously treated endometrial cancer (Sharonne Holtzman)
- UC2533, Pembrolizumab for patients with stage III MMRd/MSI-H endometrial cancer and positive ctDNA after standard of care adjuvant therapy (Paul Johannet, MD)
- DT2529, Phase II Study of Single-Agent Pembrolizumab (anti PD-1) in dMMR Early-Stage Endometrial Cancer Patients Desiring Fertility Preservation (Elisabeth Spénard)

Studies Under Development

- NRG-GY035, A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab versus Carboplatin, Paclitaxel, Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer (Amanda Nickles Fader)
- UC2229, Evaluating a Molecular based protocol for Early stage high-intermediate risk Endometrial carcinomas directed by ctDNA: The EMERGE-C Trial
- UC2417, A Study of Dactinomycin and Pembrolizumab in Patients with “Hard-to-Cure” Low-Risk and High-Risk (Risk Score 7-12) Gestational Trophoblastic Neoplasia (Lua Eiriksson)
- UC2440, One year vs two years of immunotherapy in recurrent/metastatic dMMR endometrial cancer (Floor Backes)
- UC2442, Randomized phase III study of maintenance therapy with Selinexor versus observation following carboplatin/paclitaxel for newly diagnosed FIGO 2023 stage III pMMR/p53wt endometrial cancer (Floor Backes)

Additional Notes:

Other NCTN Group Trials & Study Champions

A091903, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma **Registration to Arm 3 (nonresected R2 or metastatic disease) is Temporarily Closed to Accrual as of 06/16/2025**

Alliance: Alexander N. Shoushtari, MD

NRG Oncology: Danielle Vicus, MD

S2012, Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

NRG Oncology Study Champion: Mahdi

AGCT1531, A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors. This is an Adolescent and Young Adult (AYA) Study: Available to COG and the Adult Groups

NRG Oncology Study Champion: Covens

AGCT1532, A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors. This is an Adolescent and Young Adult (AYA) Study: It is available to COG and the Adult Groups

NRG Oncology Study Champion: Covens

COMBOMATCH

EAY191-A3, Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial (Alliance: Geoffrey Shapiro, MD, PhD, Joyce Liu, MD, Ardaman Shergill, MD)

- Cohort 1: Low Grade Serous Ovarian Cancer (LGSOC), MEK inhibitor naïve (KRAS/NRAS/HRAS, nonBRAF V600E actionable marker of interest or rare RAF fusions) **Closed to Accrual as of 04/01/2025**
- **Cohort 2: Low Grade Serous Ovarian Cancer (LGSOC), progressed on prior MEK inhibitor (not genomically selected) Open**
- Cohort 3: Pancreatic Cancer harboring any KRAS/NRAS/HRAS, non-BRAF V600E actionable marker of interest or rare RAF fusions. **Temporarily Closed to Accrual as of 07/03/2024**
- Cohort 4: Tumor agnostic harboring any KRAS/NRAS/HRAS, nonBRAF V600E actionable marker of interest or rare RAF fusions, excluding LGSOC, NSCLC, colorectal cancer, pancreatic, and melanoma. **Temporarily Closed to Accrual as of 09/05/2024**

EAY191-S3, Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial (SWOG: Reva Basho, MD, Haider Mahdi, MD, MPH)

- UC2509, Neoadjuvant carboplatin/paclitaxel/dostarlimab followed by maintenance dostarlimab for advanced stage, MMRd endometrial cancer: Is there a role for interval debulking surgery? (Brenna Swift)
- UC2515, A Phase III trial of carbo/paclitaxel followed by Tirzepatide v placebo in patients with mismatch repair proficient Stage III endometrial cancer who are overweight or obese (Angela Green, Victoria Bae-Jump, Vicky Makker, Kim Leslie)
- UC2516, A Pragmatic Randomized Open-label, Multi-Center Phase III study of Ribociclib and Letrozole vs Investigator choice SOC in Recurrent NSMP estrogen receptor positive (ER+) endometrial cancer (Julia Fehniger, Bhavana Pothuri)
- DT2418, A Preoperative Window Study of Pembrolizumab with or without Uterine-Directed Radiation Therapy for NSMP High Risk Resectable Endometrial Cancer (Matthew Harkenrider)
- DT2511, A Phase II Trial of Weekly Paclitaxel with and without Inavolisib in Recurrent Endometrial Cancer (Kristin Taylor, BJ Rimel)

Active Studies

- NRG-GY025, A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (Haider Mahdi)
- NRG-GY026, A Phase III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in HER2 Positive, Stage I-IV Endometrial Cancer (Britt Erickson)
- NRG-GY032, A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (Rainbo Blue & Taper), CCTG Protocol Number: EN.10 (CCTG Study Co-Chairs: Kathy Han, Jessica McAlpine; NRG Oncology: Matthew Powell, Lindsay Kuroki, Casey Cosgrove, Andrea Russo)

Closed Studies, primary manuscript NOT published: NRG-GY012 (Part 1 published), NRG-GY020, NRG-GY028
Closed Studies (Primary manuscript published): NRG-GY018

Biospecimen Access

MP2PRT (Cosgrove, GOG-0210)
Nav1901/CSC0148 (Secord, GOG-0258)
Nav2461/CSC0162 (Secord, GOG-0249)
Nav2801/CSC0177 (Bae-Jump, GOG-0286B)
Nav3637/CSC0272 (Mullen, GOG-0249 and GOG-0258)
NRG-GY-TS023/CSC0191 (Leslie, NRG-GY011)
NRG-GY-TS024/CSC0191 (Yang, NRG-GY011)
NRG-GY-TS029 (Madueke-Laveaux, GOG-0136-UC)
NRG-GY018-CSC0249 (Aghajanian, NRG-GY018)

Developmental Therapeutics Committee

Active Studies

- NRG-GY022, Assessment of carboplatin clearance predictors: a companion PK study to NCI sponsored clinical trials or standard of care treatments using carboplatin (Sarah Taylor, Jan Beumer)
- EAY191-N4, A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial (Shannon Westin)
- EA191-N5, A randomized trial of neratinib, a pan-ERBB inhibitor, alone or in combination with palbociclib, a CDK4/6 inhibitor, in patients with HER2+ gynecologic cancers and other solid tumors (Haider Mahdi)

Cancer Prevention and Control Committee ReportActive Studies

- NRG-CC008, A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROC) (Kathryn Pennington, Warner Huh)
- NRG-CC010, A Phase III Trial of The Impact of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer (Edward Tanner)

Closed Studies

GOG-0237, Comparative Analysis of CA-IX, p16, Proliferative Markers and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC)

GOG-0225, Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

Session Title	Head & Neck Cancer General Committee		
Date	Friday, July 25, 2025	Chair	Sue Yom, MD, PhD
Time	4:30 pm – 6:00 pm ET	Vice Chairs	Stuart Wong, MD Chris Holsinger, MD, FACS Neil Hayes, MD, MS, MPH

Meeting Agenda

Topic	Presenter
A. Head and Neck portfolio and membership update	Sue Yom, MD, PhD
B. Active Developing Studies	
<ul style="list-style-type: none"> NRG-HN013 (SWOG leading): Randomized Phase II Study of Subcutaneous Amivantamab Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma 	Paul Swiecicki, MD
<ul style="list-style-type: none"> NRG-HN015: Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched SCCHN Undergoing Salvage Surgery 	Nabil Saba, MD
<ul style="list-style-type: none"> NRG-HN2437 concept: Radiotherapy with Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial 	Loren Mell, MD
<ul style="list-style-type: none"> NRG-HN2436 concept: DeIntensification of Radiation Therapy Elective Neck Dose with Adaptation to Measurement of Oropharyngeal Cancer Patients' Human PapillomaVirus Circulating Tumor DNA (DINAMO-HPV) 	Jillian Tsai, MD
C. Review of active studies	
<ul style="list-style-type: none"> RTOG 1216: Phase III RT+cisplatin vs. RT+docetaxel+cetuximab vs. RT+cisplatin+atezolizumab for “high risk” resected HNSCC 	Julie Bauman, Paul Harari, David Rosenthal
<ul style="list-style-type: none"> NRG-HN006: Phase II-III SLN Biopsy vs. END in T1-2N0 oral cavity cancer 	Stephen Lai
<ul style="list-style-type: none"> NRG-HN008: Phase I RT + DNA-PK inhibitor in cisplatin-ineligible patients with high risk LA HNSCC 	Maura Gillison, Michael Samuels
<ul style="list-style-type: none"> NRG-HN009: Phase II-III RT with q3week cisplatin (100 mg/m² x 3) vs q1week cisplatin (40 mg/m² x 7) for locoregionally advanced HNSCC 	Paul Harari
<ul style="list-style-type: none"> NRG-HN010: Phase II HER2-targeted therapies in HER2-expressing recurrent/metastatic salivary duct/SGC 	Alan Ho

• NRG-HN011: Phase II Nivolumab vs Nivolumab+Relatlimab as Maintenance after First-line Platinum-Gemcitabine-Nivolumab in EBV Recurrent/Metastatic NPC (REMAIN)	Brigette Ma
• NRG-HN014: Phase II Neoadjuvant Immunotherapy w/ Response-Adapted Treatment vs. SOC for Resectable cSCC	Neil Gross
• RTOG 3507: Phase II ReRT +/- Pembrolizumab in Locoregionally Recurrent HNSCC	Stuart Wong
• RTOG 3521: Single-Arm Study of Toripalimab in Combination w/ Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants (TRANSPARENT)	Anna Spreafico
D. Report on publications and protocols closed to active accrual	Sue Yom
E. NRG Championed Trials updates	Sue Yom
F. NCI Head and Neck Steering Committee update	Loren Mell

Additional Notes:

NRG Head & Neck Surgery Working Group Agenda
8:00 – 10:00 AM Eastern, Friday, July 25, 2025
Room: Liberty M-P/Level 4; Marriott Marquis, Washington, DC
Chair: Erich Sturgis, MD, MPH
Co-Chair: Chris Holsinger, MD
Quality Officer: Stephen Lai, MD, PhD

I. Welcome:

- A. Drew Ridge NRG Head and Neck Surgery Working Group Travel Award**
 - a. Summer 2025 – David C. Wilde, Jr., MD (MUSC) and Zoe H. Fullerton, MD (Wash U)
Presenter: **Erich Sturgis, MD, MPH**
- B. Welcome to the New NRG Head&Neck Cancer Committee Surgical Vice Chair and NRG H&N Surgery Working Group Chair-** Floyd Christopher Holsinger, MD
Presenter: **Erich Sturgis, MD, MPH**
- C. Thank You**
Presenter: **Erich Sturgis, MD, MPH**

II. Career Investigators Experiences (8:25 a.m.):

- A. IMPT vs IMRT Randomized Phase III Multi-Institutional Trial Results**
Presenter: **Steven Frank, MD**
- B. The Path to Success: KEYNOTE-689 trial**
Presenter: **Ravindra Uppaluri, MD, PhD**

III. Brief Updates of Open / Scheduled to Open Trials (9:45 a.m.; Only 1 slide):

- A. NRG HN014-** Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment vs. Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous SCC
Presenter: **Neil Gross, MD**
- B. CCTG HN11 SELECT –** SPECT-CT Guided Treatment of Contralateral Neck in Oropharyngeal Cancer
Presenter: **John De Almeida, MD**
- C. Head and Neck Surgery Quality Officer Update-**
NRG HN006 Surgery Quality Oversight Panel and NRG HN014 Surgery Quality Oversight Panel
Presenter: **Stephen Lai, MD, PhD**
- D. Surgical Oncology Committee Chair Update**
Presenter: **Stephen Lai, MD, PhD**
- E. NRG HN006-** Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Presenter: **Stephen Lai, MD, PhD**
- F. NRG HN015-** Phase II Randomized Trial of Neoadjuvant Chemo or Chemo-Immunotherapy for Patients with Recurrent/Persistent PD-L1-Enriched SCCHN Undergoing Salvage Surgery
Presenter: **Chris Holsinger, MD**

- V. Adjourn / Next Meeting:**
VIRTUAL H&N Surgery Working Group Fall Meeting
October 24, 2025; 3p EDT/ 2p CDT, 1p MDT, 12p PDT

<https://bit.ly/NRGOnchNSurgOctober2025>



Session Title	NRG Oncology Health Care Access (HCA) Committee		
Date	7-24-2025	Chair(s)	Jennifer Wenzel, PhD, RN, CCM, FAAN
Time	10:15– 11:45 am	Vice Chair(s)	Evan Graboyes, MD, MPH, FACS

Meeting Agenda

Time	Topic	Presenter
10:15 - 10:20 am	Welcome /Announcements	Jennifer Wenzel, PhD, RN, CCM, FAAN Evan Graboyes, MD, MPH, FACS
10:20 - 10:35 am	Research Spotlight—Impact of allostatic load on mortality in Black patients with endometrial cancer	Olivia Lara, MD
10:35 - 11:00 am	CC017-Geriatric / Older Adult and HCA - Engagement and influence in concept and protocol development	Sara Hardy, MD Shearwood McClelland, III, MD
11:00 - 11:10 am	CC015: Harnessing E-Mindfulness Approaches for Living After Breast Cancer-HEAL-ABC	Patricia Ganz, MD
11:10 - 11:20 am	Rural Special Interest Group Update	Shearwood McClelland, III, MD; Na Tosha N Gatson, MD, PhD, FAAN
11:20 - 11:30 am	Education & Advancement Special Interest Group update	Victoria Bae-Jump, MD, PhD Mylin Torres, MD
11:30 - 11:40 am	Clinical Trial Enrollment Updates - Statistics/Metrics - SDMC Reports	Tara Castellano, MD Mylin Torres, MD Reena Cecchini, PhD, MS
11:40 - 11:45 am	Discussion/Wrap up	Evan Graboyes, MD, MPH, FACS

Additional Notes:

HCA Special Interest Group (SIG) Breakout Sessions

The HCA Committee Meeting and HCA SIG Breakout Sessions are open to both HCA SIG members and those interested in finding out more about who we are and what we do. The SIG Breakouts will occur on **Friday, July 25, 2025**. SIG Agendas are posted separately.

- ❖ 1:00-2:00 pm ET / HCA Research Concept Development Special Interest Group
- ❖ 4:30-5:30 pm ET / HCA Older Adult Special Interest Group

Session Title	NRG Oncology Health Care Access (HCA) Committee		
	<i>Older Adult (OA) Special Interest Group (SIG) Breakout</i>		
Date	7-25-2025	Chair(s)	William Tew, MD, FASCO
			Sindhu Kadambi, MD
Time	4:30 – 5:30 pm		

Meeting Agenda

Time	Topic	Presenter
4:30 - 4:45 pm	Welcome & Introductions	William Tew, MD, FASCO
4:45 - 5:10 pm	Active Protocol: NRG-CC107 – Integration of Geriatric Measures in a Randomized Phase III Radiation GBM Trial	Sara Hardy, MD
5:10 - 5:30 pm	Concept Review: GU-2420 – Artera-Guided Treatment of High-Risk Prostates Cancer (ART-GUIDE)	Sindhu Kadambi, MD / Adam Olson, MD

Additional Notes:

NRG Oncology Health Care Access (HCA) Committee			
Session Title	<i>Research Concept Development Special (RCD) Special Interest Group (SIG) Breakout</i>		
Date	7-25-2025	Chair(s)	Noël Arring, DNP, PhD, RN Evan Graboyes, MD, MPH, FACS
Time	1:00 – 2:00 pm		

Meeting Agenda

Time	Topic	Presenter
	• Welcome & Introductions	
	• HCA RCD Metrics	
	• Voices from the Front Lines: Effective HCA Recruitment Strategies	
	• Patient Perspective	
	• Investigator Insights	
	• NRG Resources	

Additional Notes:

Session Title	NRG Oncology Imaging Committee		
Date	July 21, 2025	Chair	Karthik Sundaram MD, PhD
Time	1:30PM-3:30PM EST	Vice Chair	Dave Fuller MD, PhD

Meeting Agenda

Time	Topic	Moderator/Presenter
1:30-1:35PM	Greetings	Karthik Sundaram MD, PhD Dave Fuller MD, PhD
1:35-1:45PM	Update NRG Theranostics Subcommittee	Thomas Ng MD, PhD
1:45-2:00PM	Disease site Updates since last meeting	
	H&N	Cynthia Wu, MD
	CNS	Virginia Hill, MD
	Breast	
	GYN	Karthik Sundaram, MD, PhD
	GI	Aoife Kilcoyne, MD
	GU	Ashesh Jani, MD Bill Hall, MD
	Lung	Andrew Baschnagel, MD
2:00-2:05PM	Update from IROC PHL for NRG Trials	Jim Gimpel, RT (R) (MR)
2:05-2:20PM	Reirradiation	Martha Matuszak, PhD
2:20-2:35PM	Heart Substructures	Elisabeth Weiss, MD
2:35-3:30PM	NRG Imaging and Medical Physics Joint Symposium	Karthik Sundaram, MD, PhD Dave Fuller, MD, PhD
	Tumor Microenvironment Imaging: Enhancing Radiation Treatment Strategies	Ying Xiao, PhD Stan Benedict, PhD
	Assessment of tumor hypoxia for radiation therapy	Periannan Kuppusamy MSc, PhD
	Characterizing radiation resistance & response with metabolic & molecular imaging	Travis Salzillo, PhD
	Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma	Nadeem Riaz, MD, MSc
	Reoxygenation dynamics during radiotherapy & the impact on local control	Joseph Deasy, PhD

Session Title	Immunotherapy Subcommittee		
Date	July 22, 2025	Chair(s)	Susanna Ulahannan, MD
Time	3-5 pm ET	Vice Chair(s)	Janice Lu, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Understand concurrent immunotherapy and radiation therapy treatment
2. Understand the role of neoadjuvant immunotherapy prior to radiation therapy
3. Understand potential risk and benefits of immunotherapy and radiation therapy

Meeting Agenda

Time	Topic	Presenter
	Introductions	Susanna Ulahannan, MD
	CME Presentation: Understanding the Therapeutic Regimens of Immunotherapy and Radiation Therapy	Julie Brahmer, MD

Additional Notes:

Session Title NRG Local Regional Breast Cancer Subcommittee

Date 7/17/2025 **Time** 1:00 pm – 2:00 pm EST (Virtual only)

Chairs Thomas Julian, MD & Douglas Arthur, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Provide information on committee mission and format.
2. Discuss local regional questions related to breast cancer.
3. Acquire insight to evolve LR clinical trials.

Meeting Agenda

Time	Topic	Presenter
1:00 - 1:05	Welcome/Introduction	Thomas Julian, MD & Doug Arthur, MD
1:05 - 1:20	Single arm phase II concept - outcomes after definitive therapy for oligoadjacent breast cancer	Rachel Jimenez, MD
1:20 - 1:35	Single fraction stereotactic ablative RT in early-stage breast cancer	Asal Rahimi, MD
1:35 - 1:50	Margin and Fraction reduction in APBI	Mark Trombetta MD
1:50 - 2:00	Closing discussion/comments	Lead by: Thomas Julian, MD & Doug Arthur, MD

Additional Notes:

Session Title Lung General Committee Meeting

Date 7/25/25 **Chair(s)** Jeffrey Bradley, MD

Time 4:30-6:15pm **Vice Chair(s)** Martin Edelman, MD
Jessica Donington, MD, PhD

Meeting Agenda

Time	Topic	Presenter
4:30-4:40	Welcome	Dr. Jeffrey Bradley
4:40-4:50	NRG-LU007	Dr. Quynh-Nhu Nguyen
4:50-5:00	NRG-LU008	Dr. Charles Simone
5:00-5:15	SWOG/NRG 1914: ASCO Updates	Dr. Charles Simone
5:15-5:30	Brain Metastases Trials	Dr. Vinai Gondì
5:30-5:45	LungMap Update	Dr. Anjali Rohatgi
5:45-5:55	MAVERICK Update	Dr. Daphna Gelblum
5:55-6:15	NCTN Lung Cancer Portfolio	Dr. Shakun Malik

Additional Notes:

Session Title	Medical Oncology Committee		
Date	July 21, 2025	Chair(s)	Corey Langer, MD
Time	11:00 am - 1:00 pm	Vice Chair(s)	Deborah Armstrong, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Understand disease-specific clinical trial outcomes and major advances from ASCO and ESMO, and other critical meetings and presentations
2. Identify unique studies involving systemic therapy in the Medical Oncology sphere
3. Itemize the accomplishments of the Pharmacy and Immunotherapy Subcommittees and their bearing on protocol conduct
4. Understand Duffy-null Associated Neutrophil Counts (DANC) is a common benign cause of neutrophil counts below institutional reference range; DANC is predominantly found in patients of African or Middle Eastern ancestry; DANC patients may experience increased exclusion from clinical trials and increased dose modification of systemic anticancer therapies.

Meeting Agenda

Time	Topic	Presenter
1100	Introductions	Corey Langer, MD
1105	ComboMatch Update	Roisin O'Cearbhaill, MD
1110	Pharmacy Subcommittee Update	Judith Smith, PharmD
1115	Immunotherapy Subcommittee Update	Susanna Ulahannan, MD
1120	CTSU Protocol-Specific EMR Templates: Overview and End User Experience	Cindy Licovali, RN, BSN, MA
1135	Introduction to Duffy-null Associated Neutrophil Counts (DANC) and implications for clinical trialists	Charlotte Story, MD
1215	GYN Disease Site Update	Bradley Corr, MD

Additional Notes:

Session Information

Session Title	NRG Medical Physics Subcommittee Virtual Agenda		
Date	July 21, 2025	Chair(s)	Ying Xiao, PhD
Time	3:30 – 5:00pm ET	Vice Chair(s)	Stanley Benedict, PhD
Room Location	Virtual Only		

2:35 pm – 3:30pm ET Virtual Only Joint Imaging and Medical Physics Symposium:
Moderators: Karthik Sundaram, MD, PhD/ Dave Fuller, MD, PhD / Ying Xiao, PhD /
Stan Benedict, PhD

Tumor Microenvironment Imaging: Enhancing Radiation Treatment Strategies

Presenters:

- **Periannan Kuppusamy, MSc, PhD** - *“Assessment of tumor hypoxia for radiation therapy”*
- **Travis Salzillo, PhD** - *“Characterizing radiation resistance and response with metabolic and molecular imaging”*
- **Nadeem Riaz, MD, MSc** - *“Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma”*
- **Joseph Deasy, PhD** - *“Reoxygenation dynamics during radiotherapy & the impact on local control”*

Meeting Agenda

Time	Topic	Presenter
3:30 – 3:32pm	Welcome, Introductions <ul style="list-style-type: none"> • Subcommittee Updates 	Ying Xiao, PhD Stanley Benedict, PhD
3:32 – 3:40pm	NCI/NCTN Updates <ul style="list-style-type: none"> • NCI Communications • NCTN Medical Physics 	Ceferino Obcemea, PhD
3:40 – 3:50pm	NRG QA Report <ul style="list-style-type: none"> • IROC Houston • IROC Philadelphia RT (Contouring & Dosimetry) • IROC Philadelphia Imaging (reporting at Imaging Committee Meeting at 2:00 – 2:05 pm) 	Stephen Kry, PhD Ying Xiao, PhD Mark Rosen, MD/ <i>Jim Gimpel, RT (R) (MR)</i>
3:50 – 4:15pm	Disease Site Reports <ul style="list-style-type: none"> • Brain • Breast • GI • GU • GYN • H&N 	Yunfeng Cui, PhD / Fang-Fang Yin, PhD Guang-Pei Chen, PhD / Jean Moran, PhD William Parker, PhD/ Gemma Davies, PhD Mihaela Rosu, PhD/Rajat Kudchadker, PhD Hayeon Kim, PhD / Cecilia Lee, PhD

- Lung
- NCORP
- Hemo

Nataliya Kovalchuk, PhD / Ping Xia, PhD
Martha Matuszak, PhD / Timothy Ritter, PhD
Yimei Huang, PhD / Tian Liu, PhD
Nataliya Kovalchuk, PhD

4:15 – 4:25pm

Modality Technology Reports

- Notable Technologies (Proton)
- Proton SBRT

Xiaoying Liang, PhD / Ying Xiao, PhD
Liyong Lin, PhD

4:25 – 4:55pm

Working Group and Other Updates

- AI for Radiotherapy Treatment Planning
- FLASH
- SFRT
- Radiomics Phantom
- Dose Summation
- Data Curation

***Please NOTE the times below for these updates:
(Presented during Imaging Committee Meeting
at 2:05 pm – 2:20 pm ET)***

- ***Reirradiation***
- ***Heart sub-structures (Presented on Imaging
Committee Meeting at 2:20 pm – 2:35 pm ET)***

Xun Jia, PhD / Quan Chen, PhD
Jennifer Zou, PhD
Heng Li, PhD
Jason Sohn, PhD
Yixiang Liao, PhD
Yi Rong, PhD

Martha Matuszak, PhD
Elisabeth Weiss, MD

4:55pm

Other Business: Questions/ General Discussions

5:00pm

Adjournment

Session Title	Ovarian Workshop		
Date	July 25, 2025	Chair(s)	Kathleen Moore, MD, MS
Time	1:00-3:00pm ET	Vice Chair(s)	Joyce Liu, MD, MPH; Rebecca Arend, MD (translational); Maggie Mullen, MD MSCI (translational, vice chair)

Learning Objectives

Following this activity, participants will be better able to:

1. Review the status of completed and ongoing NRG/GOG clinical trials on the treatment of ovarian cancer
2. Review the status of approved NRG/GOG concepts that are under development
3. Apply standard and review procedures required to design, submit, and conduct a research protocol within NRG, including ancillary data proposals
4. Assure strict quality control of NRG/GOG clinical trials

Meeting Agenda

Note: The actual order and timing of topics and discussion is subject to change, depending on availability of participants

Topic	Presenter
Introduction <ul style="list-style-type: none"> • Review of learning objectives • Statements regarding potential conflicts of interests 	
Review of Closed Studies (not terminated)	
Review of Active Studies	
Review of Approved Concepts Under Development: Concept Updates <ul style="list-style-type: none"> • OV2431: Phase II trial of SG/bevacizumab versus SOC carboplatin, PLD, bevacizumab in PSOC that has progressed on prior maintenance PARPi • RT2504: Phase II trial of balstilimab/botensilimab for recurrent clear cell ovarian cancer 	
Discussion: new therapeutic opportunities in LGSOC	
Review of New Concepts <ul style="list-style-type: none"> • OV2532: RP3 of pembrolizumab + IV or IP chemotherapy followed by pembrolizumab/olaparib maintenance in HRD test negative ovarian cancer. • RT2537: (secondary review) Tisotumab vedotin in Gyn clear cell carcinomas 	

List of Closed Studies (not terminated) – status updates since Jan 2025 meeting are in **blue**.

Study	Title	Notes
GOG-0213	A phase III randomized controlled clinical trial of carboplatin and paclitaxel (or gemcitabine) alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian peritoneal primary and fallopian tube cancer (Robert Coleman)	Lancet Oncol 2017 NEJM 2019
GOG-0262	A randomized phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel in combination with carboplatin with or without concurrent and consolidation bevacizumab in the treatment of primary stage III or IV epithelial ovarian, peritoneal or fallopian tube cancer (John K Chan)	NEJM 2016
GOG-0273	Chemotherapy toxicity in elderly women with ovarian, primary peritoneal, or fallopian tube cancer (Vivian E von Gruenigen)	Modified dose dense cohort manuscript in draft form
NRG-GY003	Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (Zamarin)	J Clin Oncol 2020
GOG-0281	RP2/3 study to assess efficacy of Trametinib in recurrent or progressive low grade serous ovarian or peritoneal cancer. (David Gershenson)	Presented IGCS 2019 Lancet 2022
GOG-0264	RP2 trial paclitaxel-carboplatin vs BEP for newly diagnosed advanced-stage and recurrent chemo-naïve sex cord stromal tumors of the ovary (Jubilee Brown)	Presented IGCS 2020 Gyn Oncol 2024
NRG-GY004	Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Joyce Liu and Ursula Matulonis)	Presented ASCO 2020 J Clin Oncol 2022 OS data presented at ESMO 2023
NRG-GY005	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Jung-Min Lee and Angeles Alvarez Secord)	Closed to accrual 10/02/2020 Total accrual 562 J Clin Oncol 2024
NRG-GY009	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and Atezolizumab vs Pegylated Liposomal Doxorubicin/Bevacizumab and Atezolizumab vs Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer (Roisin O'Cearbhaill, Carol Aghajanian)	Presented IGCS 2023
NRG-GY014 (DT1718)	A Phase II study of tazemetostat (EPZ-64438), an EZH2 inhibitor, in select gynecologic cancers (NCI CRDL LOI request). Limited sample size (n = 31), but requires genomics screening. (Ramez Eskander and David Hyman)	Closed to accrual 06/15/2022 Total accrual 62 Presented SGO 2024
NRG-GY023	A randomized phase II trial of triplet therapy (a PD-L1 inhibitor durvalumab in combination with olaparib and cediranib) vs. doublet therapy (olaparib and cediranib) vs doublet therapy (durvalumab and cediranib) vs physician choice chemotherapy in women with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal or fallopian cancer who have received prior bevacizumab (Jung-min Lee)	Presented ESMO 2023 Published CCR
NRG-GY027	A Phase IB Trial of Ipatasertib plus paclitaxel and carboplatin in women undergoing neoadjuvant chemotherapy for treatment naïve, epithelial ovarian cancer (Katherine Fuh/Kathleen Moore)	Activated 6/27/2022 Enrollment complete Total accrual: 25
NRG-GY019 (RT1753)	A Phase III Randomized Three Arm trial of paclitaxel/carboplatin compared to paclitaxel/carboplatin/maintenance letrozole versus letrozole monotherapy in patients with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum. (Amanda Nickles-Fader)	Activated 8/26/19 Enrollment complete 5/12/25! Total accrual 450

(Continued)

List of Active Studies (all metrics are as of 04/2025) – status updates since Jan 2025 meeting are in [blue](#).

Study	Title	Notes
NRG-GY021	Randomized Phase II Trial of olaparib + tremelimumab vs olaparib in platinum sensitive recurrent ovarian cancer/HRD+ and HRD. (Sarah Adams)	Closed to accrual 10/19/2020
NRG-GY022 (DT1833)	Assessment of carboplatin clearance predictors: PK protocol to allow for extra sample collection and collection of demographic data, laboratory values, and outcome data. (Liz Villaruz/Jan Beumer)	Activated 11/2019 294/350 Now enrolling male pts only
NRG-CC008 (CC1923) (NC1427) (CPC1206)	A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers (SOROCK) (Walker/Huh/Pennington)	Activated 6/2020 777/2262 Allows surgery by non-NCTN/NCORP surgeons
AGCT1531 (RT1205)	Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors (MaGIC, COG primary, AI Covens NRG)	Activated 5/2017 1068/2059
NRG-GY031 (DT2106)	A Phase IB study of combination BET protein inhibition (ZEN3694) and ATR kinase (M1774) for the treatment of recurrent ARID1A mutated clear cell and endometrioid ovarian carcinomas (Yasuto Kinose/Fiona Simpkins)	RSC 07/2021 LOI approved 6/21/22 Activated 08/31/23 13/57 New dosing amendment in development
NRG-GY033 (RT2141)	Phase II study of androgen receptor (AR) inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent AR positive adult-type ovarian granulosa cell tumor (Elizabeth Hopp/Janet Rader)	RSC 05/2022 LOI approved 1/10/24 Activated 01/22/24 17/37 On hold for interim analysis
NRG-GY036 OV2307	One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based Chemotherapy (Ying Liu/Aghajanian)	OTF 03/17/23 RSC 05/10/23 Activated 01/16/25 13/880

List of Approved Concepts Under Development – status updates since Jan 2025 meeting are in [blue](#).

Concept	Title	Notes
OV2431	Phase II trial of sacituzumab govitecan (SG)/bevacizumab versus standard of care carboplatin, liposomal doxorubicin and bevacizumab chemotherapy in patients with platinum-sensitive ovarian cancer who have progressed on prior maintenance PARP inhibitor therapy (Porter/Liu/Moore)	OTF 11/15/24 RSC 01/22/25 GCSC 03/19/25
RT2504	A Phase II Trial of balstilimab and botensilimab for recurrent clear cell carcinoma of the ovary, fallopian tube or peritoneum (Cara Matthews)	

Session Title	Particle Therapy Working Group		
Date	July 25, 2025	Chair(s)	Charles B. Simone II, MD
Time	10:15 – 11:45am ET	Vice Chair(s)	N/A

Meeting Agenda

Time (AM)	Topic	Presenter
10:15 – 10:20	Welcome Address and Chair Update	Charles Simone, II, MD
10:20-10:50	Symposium: Considerations for Proton Linear Energy Transfer (LET) in Future NRG Oncology Trials	Charles Simone, II, MD (Moderator)
	<ul style="list-style-type: none"> The Rationale for LET Optimized Proton Therapy LET-Based Proton Planning-From Development to Clinical Implementation 	David Grosshans, MD Wei Liu, PhD
10:50–11:00	Update from NCI	Jeff Buchsbaum, MD
11:00 - 11:05	Update on Proton Center Credentialing by IROC	Paige Taylor, PhD
11:05 – 11:10	Update on Medical Physics Proton	Ying Xiao, PhD
11:10 – 11:15	GU Studies: GU008, GU009, GU010, GU013	Xinglei Shen, MD
11:15 – 11:20	Lung Studies: LU008	Charles Simone, II, MD
11:20– 11:30	H&N Studies: <ul style="list-style-type: none"> HN009, HN014, CC013 HN015 (in Development) 	Dukagjin Blakaj, MD, PhD
11:30 – 11:35	GI Studies <ul style="list-style-type: none"> GI006 GI003, GI013 	Steven Lin, MD, PhD Ted Hong, MD
11:35 – 11:40	CNS Studies: BN003, BN014	Rupesh Kotecha, MD
11:40 – 11:45	Open Discussion	All

Session Title Patient-Centered Outcomes Research (PCOR) Committee Agenda

Date July 24, 2025 **Chair(s)** Ben Movsas, MD

Time 3:30-5:00 pm **Vice Chair(s)** Ron Chen, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss the statistical and logistical challenges in the design of NCORP trials with patient-centered outcomes research and proposed solutions.
2. Discuss improvement in QOL compliance and identify the next steps to further continued improvement.
3. Analyze appropriate PRO endpoints and instruments for use in NCTN Phase II and III clinical trials.

Meeting Agenda

Time	Topic	Presenter
3:30-3:35 pm	Welcome and Session Introduction	
3:35-4:00 pm	Reflections on More Than a Quarter Century of Patient-Centered Outcomes Research with NSABP/NRG Oncology	Patricia Ganz, MD
4:00-4:15 pm	Statistical and Practical Considerations in Design and Analysis of Clinical Trials with Patient-Centered Outcomes	Stephanie Pugh, PhD
4:15-4:30 pm	PRO and QOL Data Compliance Update	Marcie Ritter, PhD Kandie Dempsey, DBA, MS, RN, OCN
4:30-4:55 pm	Liaison Updates and Developing Concepts	Ben Movsas, MD Ron Chen, MD
4:55-5:00 pm	Closing Remarks	Ben Movsas, MD Ron Chen, MD

Additional Notes:

Session Title	NRG Radiation Oncology Committee		
Date	July 25, 2025	Chair(s)	Evan Wuthrick, MD
Time	8:00 – 10:00 AM	Vice Chair(s)	Charles B. Simone II, MD Diandra Ayala-Peacock, MD

Meeting Agenda

Time (AM)	Topic	Presenter
8:00 – 8:05 am	Welcome	Evan Wuthrick, MD
8:05 – 8:15 am	NCI/NCTCN Updates <ul style="list-style-type: none"> • NCI Communications • NCTN Medical Physics 	Ceferino Obcemea, PhD
8:15 – 8:20 am	NRG RO Medical Physics Subcommittee	Ying Xiao, PhD
8:20 – 8:25 am	Theranostics Subcommittee	Jeff Michalski, MD
8:25 – 8:30 am	NRG RO Particle Therapy Working Group	Charles Simone II, MD
8:30 – 8:35 am	GYN RO Working Group	Matthew Harkenrider, MD
8:35 – 8:40 am	Adaptive RT Working Group	Hyun Kim, MD
8:40 – 8:45 am	NRG Imaging Committee	Karthik Sundaram, MD, PhD
8:45 – 9:00 am	Imaging and Radiation Oncology Core Group <ul style="list-style-type: none"> • IROC Houston • IROC Philadelphia • IROC Contouring and Dosimetry 	Stephen Kry, PhD Densie Manfredi, BS Ying Xiao, PhD
9:00 – 9:15 am	ReCOG Updates Supporting NRG Clinical Trials	Charles S Mayo, PhD
9:15 – 9:55 am	Disease Site Reports – Updates on concepts near development <ol style="list-style-type: none"> H&N - Jimmy Caudell / Jason Chan Brain - Christina Tsien / Tony Wang Breast - Steven Chmura / Jose Bazan GYN - Eric Donnelly / Mark Bernard GI - William Hall / Kimberly Mak GU - Dan Krauss / Hiram Gay Lung - Stephen Chun MD / Pamela Samson Sarcoma - Philip Wong, MD / Dian Wang, MD 	Jimmy Caudell, MD Christina Tsien, MD Steven Chmura, MD Eric Donnelly, MD Kimberly Mak, MD Dan Krauss, MD Stephen Chun, MD Philip Wong, MD
9:55- 10:00am	Questions	

Session Title NRG Oncology Radiation Oncology GYN Working Group
Date July 24, 2025 **Chair(s)** Matthew Harkenrider, MD
Time 4:30 PM - 5:30 PM ET **Vice Chair(s)** Diandra Ayala-Peacock, MD
Room Location Marriott Marquis DC, Washington, DC / Georgetown University/Level 1/One Level Below Lobby (In Person Only – No A/V, **Bring Your Laptops**)

Meeting Agenda

4:30–4:32	A. Introductions / Announcements	Matthew Harkenrider, MD, Diandra Ayala-Peacock, MD
4:32-4:40	B. Future Meeting Schedule <ul style="list-style-type: none"> Virtual Interim Meeting October 10, 2025, concepts due 4-5 weeks in advance Zoom Meeting Prior to Meetings for new GYN RT Concepts (1-2 weeks prior) January 22-24, 2026 Hilton San Francisco Union Square San Francisco, CA July 16-18, 2026 Sheraton Denver Downtown Hotel Denver, CO 	Matthew Harkenrider, MD, Diandra Ayala-Peacock, MD
4:40-4:55	C. Educational Session: Management of Endometrial Cancer in the Immunotherapy Era	Casey Cosgrove, MD
4:55-5:05	D. Discussion of New Concepts <ul style="list-style-type: none"> CV2538 Personalized ctDNA Response to Determine Immunotherapy Continuation in Locally Advanced Cervical Cancer. (Rash, Monk, Mayadev) CV, GYN, IO DT2534 Single-arm Phase II alpha-particle study of [203/212Pb]Pb-PSV-359 monotherapy in patients with Persistent, recurrent or metastatic Uterine Cervix Cancer that are known to be fibroblast activation protein (FAP)-Positive. (Fabian, Kunos) DT, CV, GYN 	Dominique Rash, MD Denise Fabian, MD
5:05-5:15	E. Discussion of NRG GY037	Jyoti Mayadev, MD
5:15-5:25	F. Discussion of Previously Presented Concepts <ul style="list-style-type: none"> CV2512 (Henson): Phase II non-inferiority trial of hypo fractionated RT with cisplatin for Cervical cancer CV2346 (Glaser) CRT +/- IO for Vulva Concept DT2418 (Harkenrider) PreOp Window of Pembro +/- RT for Molecularly High Risk Operable Endometrial Cancer 	Christina Henson, MD Scott Glaser, MD Matthew Harkenrider, MD
5:25-5:30	G. Subcommittee Membership Needs H. Questions, Discussion, Concluding Remarks	Matthew Harkenrider, MD, Diandra Ayala-Peacock, MD

Session Information

Session Title	NRG Radiation Oncology Theranostics Subcommittee (TSC)		
Date	July 24, 2025	Chair	Jeff Michalski, MD
Time	3:00PM - 4:00PM Eastern Time	Vice-Chairs	Thomas Ng, MD / Oliver Sartor, MD
Room Location	In person only / Marriott Marquis Hotel / Wash., DC		

Meeting Agenda

Time	Topic	Presenter
3:00-3:10	Welcome / Introductions	Jeff Michalski, MD/ Thomas Ng, MD/ Oliver Sartor, MD
3:10-3:55	<ol style="list-style-type: none"> 1. Institutional technology survey/assessment Update <ol style="list-style-type: none"> a. AU experience (RO, NM, DR) b. RLT/RPT experience c. Dosimetry experience 2. Industry relationships 3. Concept generation/Protocol Development <ol style="list-style-type: none"> a. Data gathering of potential study topics 4. NCI Update 5. Theranostics Dosimetry / QA 6. Imaging - NM/DR / IROC 7. Medical Oncology 8. <u>Disease Sites Liaisons</u> <ol style="list-style-type: none"> a. GU b. GI c. Brain d. Lung 	<p>Thomas Ng, MD</p> <p>All</p> <p>Jacek Capala, PhD</p> <p>Ying Xiao, PhD</p> <p>Karthik Sundaram, MD/Michael Knopp, MD, PhD</p> <p>Oliver Sartor, MD</p> <p>Angela Jia, MD Kathryn Hitchcock, MD/Hyun Kim, MD</p> <p>Erik Sulman, MD/ Dan Cahill, MD</p> <p>Marty Edelman, MD</p>

e. H & N

f. Breast

g. GYN

Ana Kiess, MD / Hyu
Kang, MD

Steve Chmura, MD
Jyoti Mayadev, MD/Paul
DiSilvestro, MD

9. Future Meeting Schedule

- Hold 2 Zoom meetings between Winter and Summer NRG Oncology IN PERSON meetings. (April 10th -held and October 9th -2nd Thursday)
- January 22-24, 2026
Hilton San Francisco Union Square
San Francisco, CA
- July 16-18, 2026
Sheraton Denver Downtown Hotel
Denver, CO

3:55-4:00

Concluding Remarks and Wrap-Up
QUESTIONS / DISCUSSION

Jeff Michalski, MD/
Thomas NG, MD/
Oliver Sartor, MD

Session Title	Rare Tumor Subcommittee		
Date	July 24, 2025	Chair(s)	Allan Covens
Time	2:30 – 4:30 pm	Vice Chair(s)	Jubilee Brown

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss past, ongoing, and emerging NRG clinical trials in rare gynecologic cancers.
2. Discuss priorities and promising preclinical and translational objectives for future clinical trials.
3. Discuss outcome from preclinical workshop and strategies to increase the portfolio of clinical trials in rare gynecologic cancers.
4. Discuss potential collaborative Research Initiatives.

Meeting Agenda

Topic	Presenter
Active Studies	
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors COG lead group. Accrued /2097 (NRG- xpatients).	Covens
AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors. COG lead group. Accrued /250	Covens
A091903: A Randomized Phase II Trial Of Adjuvant Nivolumab With Or Without Cabozantinib In Patients With Mucosal Melanoma. Accrual /99 patients	Vicus
Previously Approved Studies	
RTM2504 Phase II trial of balstilimab and botensilimab for recurrent clear cell carcinoma of the ovary, fallopian tube, or peritoneum - Mathews	Mathews
Gy019R	Carey
Closed Studies	
0187, 0239, 0241, 0251, 0254, 0268, 0283, GY001, 0281, 0264, Gy016, Gy019, Gy033	
New Concepts	

<p>RT2536 An International Phase III Trial of the efficacy of adjuvant chemotherapy compared to hormonal therapy/surveillance in adult patients with advanced /metastatic or recurrent granulosa cell tumor (GHOST trial) (Gien, Ray-Coquard)</p>	<p>Reviewers: Cobb, Hopp</p>
<p>RT2537 A Phase II Study of Tissue-Factor (TF) Targeting Antibody-Drug Conjugate (ADC) Tisotumab Vedotin in Gynecologic Clear Cell Carcinomas. (Starbuck, Arend)</p>	<p>Reviewers: Edelson</p>
<p>RT2539 A randomized, open label, phase 2 trial of weekly paclitaxel versus weekly nanoparticle, albumin-bound [nab®] paclitaxel plus intermittent relacorilant in patients with relapsed adult type ovarian granulosa cell tumors (Hillman, Cobb)</p>	<p>Reviewers: Lin, Vicus</p>
<p>Working Groups</p> <ul style="list-style-type: none"> • LGSO • Clear Cell Ovary- New Translational Lead - Dr. Stover • Stromal Tumours 	<p>Carey Farley Hopp</p>
<p>Update: NRG Oncology Patient Website Analytics - Patient Advocate Group</p>	<p>Debbie Miller</p>
<p>Other Business - SGO Bridges</p>	

Additional Notes:

Session Title	Sarcoma Subcommittee		
Date	7/25/25	Chairs	Dian Wang, MD, PhD
Time	10AM-12PM	Vice Chairs	William Tseng, MD Brian Van Tine MD, PhD

Meeting Agenda

Active Studies

Phase I/II Trial of Preoperative Intensity Modulated Proton/Radiation Therapy (IMPT/IMRT) for Retroperitoneal Sarcoma Using a Simultaneous Integrated Boost
DeLaney/Yen-Lin Chen; Updated by Dr. Kevin Liu

A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High Risk Retroperitoneal Sarcoma (STRASS 2)
Updated by Dr. Dian Wang

Registry to Evaluate the Safety and Feasibility of Treating Retroperitoneal Sarcomas with Permanently Implantable LDR CivaSheet
Howell/Wang (On hold)

AEWS2231 (COG): Randomized Phase III Trial of Vincristine-Irinotecan-Regorafenib in Combination with Vincristine-Doxorubicin-Cyclophosphamide in Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Bhuvana Setty (COG PI) under the review by CTEP (PI: Bhuvana Setty, approved by CTEP, activation day unknown, OEWG date is 7/15/25); Updated by Dr. Dian Wang

Developing Concepts

NRG-RT2503: Phase IIR of SBRT and Pembrolizumab in Patients with Oligometastatic STS
Phil Wong et al; Updated by Dr. Phil Wong

Hypofractionated Alternative Radiation with MOdulation of Neoadjuvant/peri-operative immunotherapY in Sarcoma (HARMONY)
Phil Wong, CCTG trial; Updated by Dr. Phil Wong

Phase I of Dose-Escalating Trial in Treating High Grade Large STS
Dian Wang (On hold)

Phase II Study of Neoadjuvant Chemoradiation Plus Immunotherapy for Angiosarcoma
Pls-Parul Barry and Brian Van Tine; Updated by Dr. Parul Barry

Phase I Study on SBRT and Anlotinib in Relapsed/Refractory NRSTS
Susan Hiniker (COG PI) and Phil Wong (NRG Co-PI)- On Hold (Phase I on adult on hold)

A Randomized Phase II Trial of Doxorubicin + Pembrolizumab versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Seth Pollack (ECOG-ACRIN PI) and Brian Van Tine (NRG Champion)

Phase II study on Bacterial Decolonization for Preoperative Radiotherapy for Soft Tissue Sarcoma of the Lower Extremity

Adam Olson (On hold)

S2310: Phase II/III Trial Randomized Study Testing Non-Inferiority of Shorter-Course Radiation Versus Standard Fractionation for High-Risk Resectable Extremity Sarcoma

PI: Jeremy Harris. (Approved by CTEP); Updated by Dr. Jeremy Harris

Phase II Trial of Grid Sarcoma

JW Snider, Majid Mohiuddin, and Rob Griffin (On hold)

Phase II Checkpoint Inhibitor with Low Dose and High Dose RT (RadScopal) Trial of Soft Tissue Sarcoma Pulmonary Metastases

Phil Wong (On hold)

Phase Ib Trial of Preoperative Zr-Bev Immuno-PET Guided Simultaneous Integrated Boost Radiation Therapy for Locally Advanced Non-Metastatic Soft Tissue Sarcoma of Extremity and Bodywall

Wolfson (On hold)

AOST1921 (COG): Pembrolizumab in Combination with Stereotactic Body Radiation Therapy (SBRT) and Surgery in Patients with Pulmonary Recurrence of Osteosarcoma

Thomas Cash (On hold)

Phase II Trial to Investigate the Role of Peri-Operative RT in Desmoid Tumors Harboring CTNNB1 S45 Mutation

Pollock/Welliver (On hold)

AOST2032 (COG): A Feasibility and Randomized Phase II/III Study of Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Bishop (COG PI) and Meena Bedi (NRG Champion)

Phase 1b Study on of PARP Inhibitor and Radiation on Soft Tissue Sarcoma

Welliver (On hold)

New Business

Moving Forward with Sarcoma Surgical Trials

William Tseng, MD

Session Title	Translational Science Brain Tumor Working Group		
Date	July 21 st , 2025	Chair(s)	Arnab Chakravarti, MD
Time	3:00 – 4:00 pm ET	Vice Chair(s)	

Meeting Agenda

Time	Topic	Presenter
3:00 – 3:05 pm ET	Welcome and Introductions	Arnab Chakravarti, MD (Ohio State University)
3:05 – 3:25 pm ET	FET-PET versus MRI-based re-irradiation in recurrent glioblastoma: results of the prospective randomized multicentric trial - GLIAA	Prof. Dr. Anca-Ligia Grosu (University of Freiburg, Germany)
3:25 – 3:40 pm ET	Leveraging Genomic Alterations in GBM	Tamar Berger, MD, PhD (Dana Farber Cancer Institute)
3:40 – 3:55 pm ET	Discovering Structural Variant Signatures in Cancer	Gregory Raskind (Harvard University)
3:55 – 4:00 pm ET	Concluding Remarks	Arnab Chakravarti, MD

Additional Notes:

Session Title	Translational Science Genitourinary Cancer Working Group		
Date	July 25 th , 2025	Chair(s)	Phuoc Tran, MD, PhD
Time	4:30 – 6:00 pm ET	Vice Chair(s)	

Meeting Agenda

Time	Topic	Presenter
4:30 – 4:35 pm ET	Welcome and Introductions	Phuoc Tran, MD, PhD
4:35 – 5:00 pm ET	Bispecific Breakthroughs: T-Cell Engagers and Xaluritamig in Prostate Cancer Therapy	Judd Englert, MD, PhD (Amgen)
5:00 – 5:25 pm ET	Advancing multi-modal biomarker development in GU cancers with RNA, digital pathology AI, and ctDNA	Dale Muzzey, PhD (Myriad Genetics)
5:25 – 5:50 pm ET	Multi-omics analysis to unravel biomarkers of responses to immunotherapies	Luciane Tsukamoto Kagohara, PhD (Johns Hopkins University)
5:50 – 6:00 pm ET	General Translational Science Project Updates & Closing Remarks	Phuoc Tran, MD, PhD

Additional Notes:

Session Title	Translational Science GYN Working Group		
Date	Fri, Jul 25, 2025	Chair(s)	Michael Birrer, MD, PhD
Time	4:30 pm – 6:00 pm	Vice Chair(s)	Heather Lankes, PhD, MPH

Learning Objectives

Following this activity, participants will be better able to:

1. Understand GYN translational science conducted by NRG and discuss GYN translational science projects.
2. Understand the organization and operations of the NRG Biospecimen Bank and the NRG Biospecimen Access process.
3. Assure strict quality control of NRG clinical trials, including GYN translational science.

Meeting Agenda

Time	Topic	Presenter
4:30-4:35	Opening Remarks	Michael Birrer, MD, PhD Heather Lankes, PhD, MPH
4:35-4:50	Uterine Corpus Subcommittee	Vickie Bae-Jump, MD, PhD Katherine Fuh, MD, PhD
4:50-5:05	Cervix/Vulva Subcommittee	Dmitriy Zamarin, MD, PhD
5:05-5:15	Ovarian Subcommittee	Rebecca Arend, MD Maggie Mullen, MD, MSCI
5:15-5:20	Rare Tumor Subcommittee	Alessandro Santin, MD
5:20-5:35	Developmental Therapeutics	Panagiotis Konstantinopoulos, MD, PhD
5:35-5:45	Genomic and molecular characterization of biomarkers associated with self-reported race/ethnicity in high-risk endometrial cancers from NRG Oncology/GOG Protocol 210, Molecular Staging of Endometrial Cancer	Casey Cosgrove, MD
5:45-5:55	Genomic and molecular characterization of biomarkers associated with tumor angiogenesis, DNA repair, and immunologic tolerance among exceptional responders and long-term survivors in NRG Oncology/Gynecologic Oncology Group protocol 240	Krish Tewari, MD
5:55-6:00	Closing remarks	Michael Birrer, MD, PhD Heather Lankes, PhD, MPH

5:55-6:00

Closing remarks

Michael Birrer, MD, PhD
Heather Lankes, PhD, MPH

Additional Notes:

Session Title	Translational Science Head and Neck Cancer Working Group		
Date	July 25 th , 2025	Chair(s)	Neil Hayes, MD, MS, MPH
Time	1:00 – 2:00 pm ET	Vice Chair(s)	Sidharth Puram, MD, PhD

Meeting Agenda

Time	Topic	Presenter
1:00 – 1:05 pm ET	Welcome and Introductions	Sidharth Puram, MD, PhD (Washington University in St. Louis)
1:05 – 1:15 pm ET	Blood Biomarkers of Response to Neoadjuvant Immunotherapy in Cutaneous Squamous Cell Carcinoma	Nicole Schmitt, MD (Emory University)
1:15 – 1:30 pm ET	NRG-HN014: Building on Translational Opportunities in CSCC	Neil Gross, MD (MD Anderson Cancer Center)
1:30 – 1:55 pm ET	Treatment-Induced Remodeling of the T Cell Landscape in Mucosal and Cutaneous Squamous Cell Carcinoma	Joseph Zenga, MD (Medical College of Wisconsin)
1:55 – 2:00 pm ET	Concluding Remarks	Neil Hayes, MD, MS, MPH

Additional Notes:

Session Title	Translational Science Lung Cancer Working Group		
Date	July 18 th , 2025	Chair(s)	Bo Lu, MD
Time	12:00 – 2:00 pm ET	Vice Chair(s)	

Meeting Agenda

Time	Topic	Presenter
12:00 – 12:05 pm ET	Introduction and Welcome	Bo Lu, MD (University of Missouri)
12:05 – 12:25 pm ET	Radiologic Applications of Hybrid Intelligence in Oncology	Drew Torigian, MD; Jayaram Udupa, PhD (University of Pennsylvania)
12:25 – 12:45 pm ET	AI In Computational Pathology for Predicting Immunotherapy Outcomes	Mehrdad Rakaee, PhD (Oslo University)
12:45 – 1:05 pm ET	Translational Data for Durvalumab from the ADRIATIC Trial	Victoria Lai, MD (AstraZeneca)
1:05 – 1:25 pm ET	Lung Cancer Translational Science at Alliance	David Kozono, MD, PhD (Dana Farber Cancer Institute);
1:25 – 1:50 pm ET	Refining biomarker design in light of cancer evolution	Dhruva Biswas, MD, PhD (Yale University)
1:50 – 2:00 pm ET	Concluding Remarks	Bo Lu, MD

Additional Notes:

Session Title	Uterine Corpus Cancer Subcommittee		
Date	July 25, 2025	Chair(s)	Matthew Powell, MD; Ann Klopp, MD
Time	10:00am-12:00pm	Vice Chair(s)	Katherine Fuh, MD, PhD; Victoria Bae-Jump MD, PhD

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss national and international priorities, goals and initiatives in the management of Uterine cancer.
2. Discuss currently active and developing NRG clinical trials on the prevention, diagnosis, and treatment of uterine corpus cancers.
3. Discuss promising therapeutics in development and potential translational research objectives and strategies for future clinical trials.
4. Apply standards and procedures needed to design, submit, (revise), and conduct a research protocol within the NRG
5. Outline both potential barriers and potential solutions to improve enrollment to NRG clinical trials in uterine corpus cancers to include international collaboration.

Meeting Agenda

Time	Topic	Presenter
10:00–10:10	Welcome, Introductions	M. Powell & A. Klopp
10:10-10:35	Update on NRG-GY035	Dr. Amanda Nickles-Fader; Michael Toboni
10:35-11:20	<p>1. New UC concepts</p> <p>UC2531 A Randomized Phase II trial of Sacituzumab Govitecan with bevacizumab with or without Zimberelimab in patients with advanced previously treated endometrial cancer. (PIs Holtzman, Zamarin) DISCUSSANTS (BJ Rimel* (lead), Namita Khanna, Lisa Landrum)</p> <p>UC2533 Pembrolizumab for patients with Stage III MMRd/MSI-H Endometrial Cancer and positive ctDNA after standard of care adjuvant therapy. (PI Johannet) DISCUSSANTS (B. Pothuri* (lead), M. Toboni, F. Backes)</p>	

2. Uterine concepts primary to other committees.

DT2529 Phase II Study of Single-agent Pembrolizumab (anti PD-1) in dMMR Early Stage Endometrial Cancer Patients Desiring Fertility Preservation (PIS Covens, Spenard, Swift)
DISCUSSANTS: (Emma Barber* (Lead), L Kuroki, C. Cosgrove)

Potential Discussants: BJ Rimel, K. Fuh, B. Pothuri, Namita Khanna, Emma Barber, Lisa Landrum, V Bae-Jump, B Slomovitz, H MacKay, F Backes,

11:20-11:30

11:30-11:45

Review of Open and Recently Closed Trials

H MacKay, R Eskander, F. Backes, M Powell, B. Erickson, L Kuroki, C Cosgrove,

11:45-11:55

Review of Studies in Development

V Makker, A Fader, A. Secord, A. Klopp, M. Toboni, N. Horowitz, Lua Eiriksson

11:55-12:00

Additional Discussion / Questions

open

Session Title	Veterans Affairs/Military Treatment Facility (VA-MTF) Subcommittee Meeting (Virtual Only)		
Date	July 21, 2025	Chair(s)	Vlad Sandulache, MD, PhD
Time	12:00 pm – 1:00 pm ET	Vice Chair(s)	Maria Kelly, MB, BCh, BAO, FACR, FASTRO, FAWWR

Meeting Agenda

Time	Topic	Presenter
12:00 pm ET	Welcome	Drs. Sandulache and Kelly
	Updates on accrual	Dr. Sandulache
	Trials & trial concepts	
	FORTE (colorectal prevention study)	Dr. Schoen (or team member)
	HN015 (recurrent HNSCC)	Dr. Chinn
	HN2437 (cisplatin ineligible HNSCC)	Dr. Takiar
	NRG GU2420 (Artificial Intelligence-Guided Treatment of High Risk Prostate Cancer (ART-GUIDE))	Dr. Olson
	GI012 (Phase III Trial of Systemic Treatment +/-Liver SBRT in BCLC Class C Hepatocellular Cancer With Macrovascular Invasion)	Dr. Wo
	NRG-HN013 (A Randomized Phase II Study of Amivantamab versus Cetuximab in Immunocompromised Patients with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma)	Dr. Geiger
	Open discussion	Led by Dr. Sandulache

Additional Notes: NA



NRG *Oncology*

2025 SUMMER MEETING
WASHINGTON DC

NRG ONCOLOGY
Institutional Accrual

#NRG2025

Accrual For Agenda Book from 1/1/2025 to 6/30/2025 Run Date: 7/15/2025				
NRG Main Member (Network)	CTEP ID	Accrued to NRG Studies and Credited to NRG	Accrued to Non-NRG NCTN Studies and Credited to NRG	Total
AdventHealth Orlando	FL086	1	0	1
Allan Blair Cancer Centre	11076	3	0	3
Allegheny General Hospital	PA009	3	2	5
Arizona Center for Cancer Care-Peoria	AZ127	1	0	1
Arthur J E Child Comprehensive Cancer Centre	11134	6	0	6
Ascension Alexian Brothers - Elk Grove Village	IL280	0	0	0
Aurora NCI Community Oncology Research Program	AURORA	16	26	42
Avera Cancer Institute	SD021	5	6	11
Banner University Medical Center - Tucson	AZ017	15	0	15
Baptist Health Cancer Research Network	BHCRN	8	32	40
Baptist MD Anderson Cancer Center	FL003	4	2	6
Bay Pines VA Healthcare System	FL051	22	0	22
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	TX041	1	4	5
Baystate Medical Center	MA004	1	0	1
BCCA-Vancouver Cancer Centre	11081	11	0	11
Boston Medical Center	MA043	1	2	3
Cancer Research Consortium of West Michigan NCORP	CRCWM	12	0	12
Cancer Research for the Ozarks NCORP	OZARKS	23	0	23
Cancer Research of Wisconsin and Northern Michigan Consortium	CROWN	55	3	58
Cancer Trials Ireland	ICORG	5	0	5
Carle Cancer Center NCI Community Oncology Research Program	CARLE	23	0	23
Carolinas Medical Center/Levine Cancer Institute	NC042	18	0	18
Cedars-Sinai Medical Center	CA016	15	9	24
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont	11065	6	0	6
Chinese University of Hong Kong-Prince of Wales Hospital	34003	4	0	4
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)	11073	31	0	31

CHUM - Centre Hospitalier de l'Universite de Montreal	11062	10	0	10
City of Hope Comprehensive Cancer Center	CA043	13	7	20
CIUSSEMTL-Hopital Maisonneuve-Rosemont	11060	0	0	0
Columbia University Minority Underserved NCORP	COLUMBIA	12	0	12
Columbus NCI Community Oncology Research Program	COLUMBUS	3	0	3
CommonSpirit Health Research Institute	CORA	16	6	22
Community Cancer Center North	IN006	0	0	0
Cooper Hospital University Medical Center	NJ036	10	5	15
Corewell Health William Beaumont University Hospital	MI005	2	4	6
Covenant Medical Center-Lakeside	TX054	0	0	0
Cross Cancer Institute	11132	0	0	0
CWRU Case Comprehensive Cancer Center LAPS	LAPS-OH029	49	1	50
Dana-Farber / Partners CancerCare LAPS	LAPS-MA036	16	0	16
Danbury Hospital	CT030	0	0	0
Dartmouth College - Dartmouth Cancer Center LAPS	LAPS-NH012	13	1	14
Dayton NCI Community Oncology Research Program	DAYTON	0	0	0
Delaware/Christiana Care NCI Community Oncology Research Program	CHRISTIANA	12	0	12
Dell Seton Medical Center at The University of Texas	TX063	2	1	3
Duke University - Duke Cancer Institute LAPS	LAPS-NC010	15	1	16
Edward Hospital/Cancer Center	IL104	3	1	4
Emory University - Winship Cancer Institute LAPS	LAPS-GA005	19	1	20
Essentia Health NCI Community Oncology Research Program	ESSENTIA	7	0	7
Fox Chase Cancer Center	PA086	4	6	10
Fred Hutchinson Cancer Research Center LAPS	LAPS-WA008	7	3	10
Froedtert and the Medical College of Wisconsin LAPS	LAPS-WI013	24	1	25

Geisinger Cancer Institute NCI Community Oncology Research Program	GEISINGER	14	2	16
George Washington University Medical Center	DC014	10	1	11
Georgia Cares Minority Underserved NCORP	GACARES	17	0	17
Georgia NCI Community Oncology Research Program	GEORGIA	10	5	15
Global Oncology Trials Japan	GOTJ	2	0	2
Greater Baltimore Medical Center	MD018	1	0	1
Gulf South Minority Underserved NCORP	GULFSOUTH	27	1	28
Hackensack University Medical Center	NJ022	5	0	5
Hartford Hospital	CT009	3	6	9
Hawaii Minority Underserved NCORP	HAWAII	14	0	14
Heartland Cancer Research NCORP	HEARTLAND	23	0	23
Henry Ford Hospital	MI026	5	0	5
Houston Methodist Hospital	TX036	2	0	2
Indiana University/Melvin and Bren Simon Cancer Center	IN007	32	2	34
Intermountain Medical Center	UT056	12	1	13
Iowa-Wide Oncology Research Coalition NCORP	IWORC	10	7	17
James A. Haley Veterans Affairs Hospital	FL064	0	0	0
Jewish General Hospital	11116	5	0	5
JHU Sidney Kimmel Comprehensive Cancer Center LAPS	LAPS-MD017	10	2	12
Juravinski Cancer Centre at Hamilton Health Sciences	11183	1	0	1
Kaiser Permanente NCI Community Oncology Research Program	KAISER	437	8	445
Kaiser Permanente-Gaithersburg Medical Center	MD198	27	0	27
Kantonsspital Aarau	67029	3	0	3
Lahey Hospital and Medical Center	MA017	1	0	1
Lankenau Medical Center	PA125	1	0	1
Laura and Isaac Perlmutter Cancer Center at NYU Langone	NY011	26	0	26
Legacy Good Samaritan Hospital and Medical Center	OR013	2	0	2
Loyola University Medical Center	IL017	3	1	4
MaineHealth Cancer Care Network	MAINE	15	2	17
Mayo Clinic LAPS	LAPS-MN026	19	4	23
Medical University of South Carolina Minority Underserved NCORP	MUSC	10	0	10

MedStar Franklin Square Medical Center/Weinberg Cancer Institute	MD029	0	1	1
Memorial Sloan-Kettering Cancer Center LAPS	LAPS-NY016	14	1	15
Metro Minnesota Community Oncology Research Consortium	METROMIN	52	0	52
Miami Cancer Institute	FL078	20	5	25
Miami Valley Hospital	OH084	4	4	8
Michigan Cancer Research Consortium NCORP	MCRC	19	0	19
Michigan Healthcare Professionals Farmington	MI310	7	0	7
Michigan State University	MI038	0	0	0
Moffitt Cancer Center	FL065	18	1	19
Montana Cancer Consortium NCORP	MONTANA	8	0	8
Montefiore Minority Underserved NCORP	MONTEFIORE	14	2	16
Mount Sinai Hospital	NY021	24	3	27
MU Health - University Hospital/Ellis Fischel Cancer Center	MO036	4	1	5
National Cancer Centre Singapore	47005	6	0	6
National Institutes of Health Clinical Center	MD004	0	0	0
NCORP of the Carolinas (Prisma Health NCORP)	GREENVILLE	4	0	4
Nebraska Methodist Hospital	NE007	5	6	11
Nevada Cancer Research Foundation NCORP	NCRF	1	2	3
New Mexico Minority Underserved NCORP	NEWMEXICO	32	1	33
New York-Presbyterian/Brooklyn Methodist Hospital	NY075	16	0	16
NorthShore University HealthSystem-Evanston Hospital	IL018	3	1	4
Northwell Health NCORP	NORTHWELL	33	0	33
Northwestern University LAPS	LAPS-IL036	17	0	17
Norton Hospital Pavilion and Medical Campus	KY049	7	0	7
Odette Cancer Centre- Sunnybrook Health Sciences Centre	11118	22	0	22
Ohio State University Comprehensive Cancer Center LAPS	LAPS-OH007	59	1	60
Oklahoma Cancer Specialists and Research Institute-Tulsa	OK037	4	2	6
Oregon Health and Science University	OR010	4	1	5
Orlando Health Cancer Institute	FL020	1	1	2

Ottawa Hospital and Cancer Center-General Campus	11025	4	0	4
Pacific Cancer Research Consortium NCORP	PCRC	34	0	34
Parkview Regional Medical Center	IN181	4	3	7
Penn State Milton S Hershey Medical Center	PA042	12	0	12
Peter MacCallum Cancer Centre	3003	0	0	0
Piedmont Hospital	GA027	0	3	3
ProMedica Flower Hospital	OH012	3	0	3
Puerto Rico Minority Underserved NCORP	PUERTORICO	31	0	31
Reading Hospital	PA107	2	4	6
Regents of the University of Michigan	LAPS-MI014	9	0	9
Rhode Island Hospital	RI005	3	0	3
Riverside Methodist Hospital	OH008	11	1	12
Roswell Park Cancer Institute LAPS	LAPS-NY158	0	0	0
Rush University Medical Center	IL043	6	0	6
Rutgers Cancer Institute of New Jersey	NJ066	22	3	25
Saint Joseph Hospital - Orange	CA087	2	1	3
Saint Joseph's Hospital and Medical Center	AZ009	0	0	0
Sanford NCI Community Oncology Research Program of the North Central Plains	SANFORD	11	3	14
Sarah Cannon Cancer Center	TN047	3	2	5
Saskatoon Cancer Centre	11120	9	0	9
Seoul National University Hospital	43002	1	0	1
Southeast Clinical Oncology Research Consortium NCORP	SCOR	26	1	27
Stanford Cancer Institute Palo Alto	CA141	20	0	20
State University of New York Upstate Medical University	NY141	8	3	11
Stony Brook University Medical Center	NY184	5	5	10
Stroger Hospital of Cook County Minority Underserved NCORP	STROGER	12	1	13
Summa Health System - Akron Campus	OH055	1	2	3
Sutter Cancer Research Consortium	SUTTER	13	29	42
The James Graham Brown Cancer Center at University of Louisville	KY002	6	20	26
The Research Institute of the McGill University Health Centre (MUHC)	11318	9	0	9
The US Oncology Network	USONC	0	0	0
Thomas Jefferson University Hospital LAPS	LAPS-PA121	13	10	23
Thompson Cancer Survival Center	TN038	0	0	0
Tibor Rubin VA Medical Center	CA041	0	0	0

Ottawa Hospital and Cancer Center-General Campus	11025	4	0	4
Pacific Cancer Research Consortium NCORP	PCRC	34	0	34
Parkview Regional Medical Center	IN181	4	3	7
Penn State Milton S Hershey Medical Center	PA042	12	0	12
Peter MacCallum Cancer Centre	3003	0	0	0
Piedmont Hospital	GA027	0	3	3
ProMedica Flower Hospital	OH012	3	0	3
Puerto Rico Minority Underserved NCORP	PUERTORICO	31	0	31
Reading Hospital	PA107	2	4	6
Regents of the University of Michigan	LAPS-MI014	9	0	9
Rhode Island Hospital	RI005	3	0	3
Riverside Methodist Hospital	OH008	11	1	12
Roswell Park Cancer Institute LAPS	LAPS-NY158	0	0	0
Rush University Medical Center	IL043	6	0	6
Rutgers Cancer Institute of New Jersey	NJ066	22	3	25
Saint Joseph Hospital - Orange	CA087	2	1	3
Saint Joseph's Hospital and Medical Center	AZ009	0	0	0
Sanford NCI Community Oncology Research Program of the North Central Plains	SANFORD	11	3	14
Sarah Cannon Cancer Center	TN047	3	2	5
Saskatoon Cancer Centre	11120	9	0	9
Seoul National University Hospital	43002	1	0	1
Southeast Clinical Oncology Research Consortium NCORP	SCOR	26	1	27
Stanford Cancer Institute Palo Alto	CA141	20	0	20
State University of New York Upstate Medical University	NY141	8	3	11
Stony Brook University Medical Center	NY184	5	5	10
Stroger Hospital of Cook County Minority Underserved NCORP	STROGER	12	1	13
Summa Health System - Akron Campus	OH055	1	2	3
Sutter Cancer Research Consortium	SUTTER	13	29	42
The James Graham Brown Cancer Center at University of Louisville	KY002	6	20	26
The Research Institute of the McGill University Health Centre (MUHC)	11318	9	0	9
The US Oncology Network	USONC	0	0	0
Thomas Jefferson University Hospital LAPS	LAPS-PA121	13	10	23
Thompson Cancer Survival Center	TN038	0	0	0
Tibor Rubin VA Medical Center	CA041	0	0	0

University of Rochester LAPS	LAPS-NY167	9	2	11
University of South Alabama Mitchell Cancer Institute	AL068	0	3	3
University of Tennessee - Knoxville	TN021	0	2	2
University of Tennessee Health Science Center	TN030	0	0	0
University of Texas Health Science Center at San Antonio	TX059	3	2	5
University of Texas MD Anderson Cancer Center LAPS	LAPS-TX035	30	4	34
University of Texas Medical Branch	TX045	0	1	1
University of Texas Southwestern Medical Center LAPS	LAPS-TX011	8	1	9
University of Utah - Huntsman Cancer Institute LAPS	LAPS-UT003	8	4	12
University of Vermont and State Agricultural College	VT004	14	0	14
University of Virginia Cancer Center	VA009	16	0	16
University of Wisconsin Carbone Cancer Center LAPS	LAPS-WI020	22	2	24
UPMC Hillman Cancer Center LAPS	LAPS-PA015	89	3	92
Upstate Carolina Consortium Community Oncology Research Program	UPSTATE	17	0	17
USC Norris Comprehensive Cancer Center LAPS	LAPS-CA011	1	15	16
Vanderbilt University - Ingram Cancer Center LAPS	LAPS-TN008	1	0	1
VCU Massey Cancer Center Minority Underserved NCORP	VCU	21	16	37
Wake Forest University Health Sciences	NC002	4	0	4
Walter Reed National Military Medical Center	MD001	0	0	0
Washington University - Siteman Cancer Center LAPS	LAPS-MO011	34	4	38
Wayne State University - Karmanos Cancer Institute LAPS	LAPS-MI020	10	0	10
WellSpan Health-York Hospital	PA047	15	0	15
West Virginia University Charleston Division	WV004	1	4	5
West Virginia University Healthcare	WV025	6	12	18
Western States Cancer Research NCORP	WESTERN	0	0	0
Wisconsin NCI Community Oncology Research Program	WINCORP	14	0	14
Women and Infants Hospital	RI012	22	8	30
Women's Cancer Center of Nevada	NV049	25	0	25

Yale University - Yale Cancer Center LAPS	LAPS-CT018	19	7	26
Yonsei University Health System-Severance Hospital	43027	0	0	0

NRG2025 Travel Awardees

Congratulations to all of the members who received travel awards to the NRG 2025 Summer Meeting. We look forward to your involvement and contributions!

Haley Appel, *Baptist Health*

Rebecca Baca, *The University of New Mexico*

Edward Bleta, *Trinity Health*

Anne Brooks, *HCA Healthcare*

Jason Chan, *University of California San Francisco*

Chasity Cupp, *University of Kansas Medical Center*

Cynthia Dwight, *Medical College of Wisconsin*

Valerie Ferguson, *Hawaii Pacific Health Medical Group*

Timothy Guinn, Jr., *University of Florida*

Nedra Johnson, *Medical College of Wisconsin*

Haley Kelly, *University of Arkansas for Medical Sciences*

Sarah Lewis, *Beebe Healthcare*

Elena Nelson, *University of Florida*

Fauzia Riaz, *Stanford University*

Soumon Rudra, *Emory University*

Sponsors & Exhibitors

Platinum Sponsor

AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives. Our commitment is measured by the impact we make – to patients, to our communities, and to the world. Our approximately 50,000 employees strive to make a remarkable impact that lasts, driven by our compassion for people, commitment to innovation and inclusion, service to the community and uncompromising integrity. Today our products help more than 60 million people living in more than 175 countries, and we are making significant advancements with a robust pipeline of potential new medicines as we look to find the treatments of tomorrow.

Platinum Sponsor

GSK

GSK is a focused, global biopharma company. Our purpose is to unite science, technology and talent to get ahead of disease together and positively impact the health of billions of people.

AstraZeneca

We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.

Caris Life Sciences

Caris Life Sciences is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. To learn more, please visit www.CarisLifeSciences.com.

Sponsors & Exhibitors

Corcept Therapeutics

Corcept Therapeutics is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more than 25 years, Corcept's singular focus on cortisol modulation has led to the discovery of more than 1,000 proprietary selective cortisol modulators that have the potential to deliver improved patient outcomes across a wide range of diseases. In February 2012, the company introduced Korlym® (mifepristone), the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing's syndrome. Corcept is headquartered in Menlo Park, California. For more information, visit Corcept.com.

Eisai

As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

Flatiron

Flatiron Health is a health tech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Our [partnership](#) with NRG Oncology exemplifies our commitment to advancing cancer research by broadening Flatiron Clinical Pipe™ use cases to include NCTN sponsored studies. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

Gilead Sciences

Helping to Bring More Life to People with Cancer™

We're innovating with next-generation therapies, combinations and technologies to expand our oncology portfolio and bring more life to people with cancer. Gilead and Kite are continuing to expand our oncology platform across major pathways, including cell therapies and medicines for difficult-to-treat metastatic cancers.

We refuse to accept that cancer can still take the ones we love, and we're actively collaborating with the oncology community in pursuit of equitable access to cancer care.

IROC

The Imaging and Radiation Oncology Core (IROC) provides integrated radiation oncology and diagnostic imaging quality control programs in support of clinical trials conducted by NRG Oncology and the other Network Groups in the National Clinical Trials Network. IROC staff are here to answer study data submission related radiation therapy and diagnostic imaging questions from investigators or other clinical research professionals.

Sponsors & Exhibitors

Jazz Pharmaceuticals

At Jazz Pharmaceuticals, our purpose is to innovate to transform the lives of patients and their families.

We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options – so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.

Lumonus

Lumonus has developed an innovative software platform designed to support radiation oncology care teams in the delivery of high-quality and efficient cancer care by leveraging user-centric workflows, cloud-native architecture, process automation and Artificial Intelligence.

Merck

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Natera

Signatera is a custom-built circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) assessment and treatment response monitoring in patients previously diagnosed with cancer. Signatera’s performance has been clinically validated in multiple solid tumors including colorectal, breast, and bladder cancers as well as for immunotherapy response monitoring.

Verastem

Verastem Oncology is late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com and follow us on [LinkedIn](#).

Exhibit Hall Schedule:

Thursday 7:00am – 6:00pm

Friday 7:00am – 5:30pm

Saturday 7:00am – 1:00pm

Complimentary coffee, tea, and soft drinks will be served in the exhibit area at specified times on each day that exhibits are open.



EXPLORE ZEJULA

AS A POTENTIAL TREATMENT
OPTION FOR YOUR PATIENTS



Learn more at ZEJULAHCP.com

Intended for US Healthcare Professionals.

Trademarks are property of their respective owners.

©2025 GSK or licensor.
PMUS-NRPJRNA250002 April 2025
Produced in USA.

GSK



EXPLORE JEMPERLI

as a potential treatment option
for your patients



Learn more at
JEMPERLIHCP.COM

Intended for US Healthcare Professionals.

Trademarks are owned by or licensed to the GSK group of companies.



©2025 GSK or licensor.
PMUS-DSTJRNA250002 February 2025
Produced in USA.

Transfer up to 100% of EHR trial data in just a few clicks

Flatiron Clinical Pipe™ is an EHR-to-EDC app that seamlessly captures and transfers study data between systems, reducing data monitoring queries and eliminating frustrating manual data entry.



Integrate with the workflows you already use

Flatiron Clinical Pipe™ is embedded directly into your EHR to seamlessly integrate with your existing workflows, allowing you to onboard quickly and reduce complexity.

Transfer more data types to get more time back in your day

Flatiron Clinical Pipe™ enables the capture and transfer of both structured and unstructured data in only a few clicks—including labs, medications, vital signs, adverse events, and past medical/surgical history, among many more. This means no more time-intensive and duplicative data entry tasks and more time back in your day.

No added research costs

Once installed at your site, Flatiron Clinical Pipe™ can be used with any sponsor or contract research organization that also uses the technology—completely free of charge.

“[The data entry time for] a patient visit went from 45 minutes to 5...which is pretty substantial.”

Eric T. Smith, MST, MBA

Former Senior Director, Clinical Research
Services Office, Oregon Health & Science University

Achieve fast and efficient set-up

Flatiron Clinical Pipe™ only requires a brief, one-time integration into the EHR. After the one-time setup is complete, you may use the product on any Flatiron Clinical Pipe™-enabled protocol.

Experience exceptional training and support

Flatiron's dedicated Network Operations team provides top-tier implementation and change management support including 1:1 training, group training, onsite and virtual support, and a dedicated advocate to listen to feedback and communicate needs to the broader Flatiron team.

Remember one less password

Flatiron Clinical Pipe™ uses a secure login process that does not require passwords, giving you one less thing to remember everyday.

Receive fewer data monitoring queries

Data transferred with Flatiron Clinical Pipe™ completely mirrors the EHR, drastically reducing the need for data monitoring queries and the need to obtain and maintain reference ranges, allowing you to focus on true data quality and discrepancy issues rather than transcription.

Shape your technology needs

Flatiron continually collects direct and specific end-user feedback on our technology through rigorous research studies and long-standing site relationships, giving us a deep set of learnings that help to optimize our technology to give you a better experience.

Adhere to the highest compliance standards

Flatiron provides strict security, process and admin controls to meet SOC-2 and HITRUST CSF requirements (including certification against all 5 Trust Services Criteria) and align with HIPAA, GDPR and 21 CFR 11 regulations. All data is encrypted both in transit and at rest.

BY THE NUMBERS

5+ years

Flatiron Clinical Pipe™ has been used for over 5 years, giving you confidence in our proven technology.

85 Sites and Counting

Flatiron Clinical Pipe™ is connected with 85+ community oncology and academic medical center sites, representing 300 unique locations and 4X growth since 2022.


0 worry

Data transferred with Flatiron Clinical Pipe™ completely mirrors the EHR, ensuring quality of data entered into the EDC and reducing future queries.

FOR MORE INFORMATION

Have questions about Flatiron Clinical Pipe™ or want to know more about how we can support clinical research at your site?

Let us know at
crsupport@flatiron.com



Physician Dosimetry

Copilot

AI powered copilots embedded through your workflow

Radiation oncology intelligence layer

YOUR LUMONIUS AI WORKFLOW

Consult

Summarize patient documents with insight for
faster + insightful consult prep

Prescribe

Rich standardized prescribing for
clarity downstream to the care team

Document

Automate documentation to
boost productivity + RCM performance

Plan

Comprehensive planning automation to
improve quality, increase access + reduce costs

Improve

Embedded analytics for
real time data driven decisions

Integration with all major EMR, OIS + TPS



Quality, efficiency+ access

made easier

QUALITY

97%

Guideline adherence

EFFICIENCY

102mins

Reduction in admin burden per patient

30%

Reduction in dosimetry costs

ACCESS

2 day


Improvement in planning time

RCM

2%

Uplift in collections

Let's partner together to transform cancer care



Visit our booth at NRG to find out more – Exhibit #09



Thank You

NRG Oncology would like to thank and acknowledge the following companies for providing Independent Medical Education (IME) grant support associated with the 2025 Summer Semiannual Meeting of NRG Oncology.

ABBVIE

ASTRAZENECA

COHERUS

COOPER SURGICAL

EXACT SCIENCES

GSK

NOVARTIS

PFIZER

SIEMENS/VARIAN MEDICAL SYSTEMS



Thank You

The NRG Oncology Foundation and The GOG Foundation would like to thank and acknowledge the following companies for providing Independent Medical Education (IME) grant support associated with the 2025 NRG/GOG Joint Educational Symposium entitled:

“Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors”

ABBVIE


GILEAD

NRG ONCOLOGY


Future Meeting Dates & Locations



Jan. 22-24, 2026 - San Francisco, CA



July 16-18, 2026 - Denver, CO



January 28-30, 2027 - Las Vegas, NV